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GeNeRAl iNTRoduCTioN
Cytotoxic chemotherapy (Taxanes and taxane combinations)
Robert J. van Soest, Ellen S. de Morée, Cora N. Sternberg and Ronald de Wit.
In: Saad F and  Eisenberger M.A. (eds.), Management of Castration Resistant Prostate Cancer, 
Current Clinical Urology, Springer 
CHAPTeR 1
inTroduCTion
Urologists have traditionally been the primary caregivers for patients with prostate 
cancer and patients were referred to medical oncologists only in very late stages. With the 
advent of docetaxel chemotherapy, this pattern has drastically changed.  This has led to 
better cooperation among physicians and important phase III studies which have shown 
a survival advantage not only with docetaxel, but also with cabazitaxel chemotherapy, 
novel hormonal therapies, immunotherapy and novel radiation therapy. Oncologists are 
highly skilled in administering chemotherapy. With more than two decades of experience 
with taxanes in a variety of solid tumors, in-depth knowledge and understanding of 
potential drug-drug interactions, dose modifications,  strategies for dealing with patients 
with medical comorbidities and toxicities has been attained. Since most patients remain 
with their medical oncologist during the later stages of their disease, post-docetaxel 
registrations of abiraterone and enzalutamide have in most cases been spearheaded by 
medical oncologists, with similar arguments about potential drug- drug interactions and 
handling of toxicities. Oncologists have primarily though not exclusively been involved in 
the drug development of novel hormonal therapies in the post-docetaxel setting. As these 
hormonal agents become more widely used prior to chemotherapy, both urologists and 
medical oncologists will most likely be more intimately involved in their administration. 
The right treatment sequence and the most optimal choice for an individual patient still 
requires further research and development.  In this chapter, we have eluded to various 
predictive factors for benefit with abiraterone and with docetaxel that may impact the 
treatment choice. In addition, there is an increasing concern about the effectiveness 
of taxanes post- new generation AR inhibiting drugs. Whoever treats patients with 
castration-resistant prostate cancer should be encouraged to evaluate their patients in a 
multidisciplinary team approach.  
MiToxanTrone
In 1996 Tannock et al. reported on a phase III study involving 161 patients with 
metastatic castration resistant disease who were randomized to mitoxantrone 12mg/m2 
every 3-weeks plus prednisone or prednisone alone [1]. Pain response was the primary 
endpoint and this was achieved in 29% of patients treated with mitoxantrone, compared 
to 12% of patients treated with prednisone (p=0.01). Despite superior pain response rates, 
mitoxantrone did not impact overall survival (OS) which was 12 months in both treatment 
arms, p=0.27). A trial comparing mitoxantrone plus hydrocortisone versus hydrocortisone 
alone was conducted by the Cancer and Leukemia Group B (CALBG) to evaluate OS. No 
survival benefit was observed in this study, although there was a small but significant 
increase in time to disease progression in the mitoxantrone arm [2]. Based upon these 
results, the Food and Drug Administration (FDA) approved mitoxantrone as palliative 
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chemotherapy in patients with castration-resistant prostate cancer. Consequently, 
mitoxantrone became the control arm in the two pivotal phase III trials investigating 
docetaxel in patients with mCRPC. Anthracyclines and more specifically mitoxantrone 
were the standard for cytotoxic chemotherapy until the introduction of docetaxel in 2004 
and treatment of men with metastatic castration-resistant prostate cancer (mCRPC) was 
primarily driven by symptom palliation. 
doCeTaxel
Microtubules are the main target of taxanes, which bind to a specific binding 
site on the tubulin β-subunit. Taxanes suppress microtubule dynamics by promoting 
tubulin assembly and stabilizing microtubules, blocking mitosis at the metaphase/
anaphase transition, which results in cell death [3-5]. It has been recently shown that AR 
transport is facilitated by microtubules and the motor protein dynein. By interfering with 
microtubules,  taxanes also inhibit AR nuclear transport, a known mechanism of antitumor 
activity in mCRPC [6-8] (Figure 1). 
Figure 1 
Adapted from Thadani-Mulero M et al. Cancer Res 2012;72:4611-4615 (with permission) 
Permission CR pending 
©2012 by American Association for Cancer Research 
figure 1.  Adapted from Thadani-Mulero M et al. Cancer Res 2012;72:4611-4615 (with permission)
Proposed model of taxane mechanism of action in prostate cancer. AR associates with microtubules and translocates to the 
nucleus via the motor protein dynein. Taxanes inhibit depolymerzation of microtubules and block microtubules dynamics. By 
interfering with microtubule dynamics, taxanes cause a cell cycle arrest in the G2/M phase, and inhibit AR nuclear translocation 
as an additional mechanism of action in mCRPC.
The mechanisms of action of enzalutamide (MDV3100) and abiraterone are also shown. Enzalutamide exerts its effect by 
inhibiting AR nuclear translocation, DNA-binding and co-activator recruitment.  Abiraterone inhibits androgen biosynthesis by 
irreversibly blocking CYP17A1, a crucial enzyme in steroidogenesis.
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Following phase I/II studies yielding PSA responses, pain responses, and objective 
tumor responses for docetaxel [9, 10], two large phase III trials TAX327 and SWOG 99-
16 were initiated [11, 12]. TAX327 was conducted in 1006 men with mCRPC who were 
randomized to receive 3-weekly docetaxel (75 mg/m2), weekly docetaxel (30 mg/m2) or 
3-weekly mitoxantrone (12 mg/m2), each with prednisone [11]. OS of patients who were 
treated with docetaxel in the 3-weekly regime was superior as compared to mitoxantrone 
with an OS of 19.2 vs 16.3 months (HR 0.79, 95%CI 0.67-0.93) in the final analysis [13]. The 
docetaxel 3-weekly arm also showed better palliation, with more patients having pain 
(35% vs. 22%, p=0.01) and quality of life responses (22% vs 13%, p=0.009) as compared 
to mitoxantrone . The docetaxel weekly schedule showed a trend towards improved 
OS, but did not reach statistical significance. The TAX327 updated survival analysis also 
contained a post-hoc analysis which demonstrated that the trends in OS were consistent 
among several subgroups of patients based on age (<68 vs. ≥68 years), pain vs. no pain at 
baseline, and baseline PSA <115 vs. ≥115 ng/ml.
Neutropenia was the most common observed grade 3 / 4 toxicity and occurred more 
frequently in patients receiving 3-weekly docetaxel (32%). Despite the high incidence of 
neutropenia, febrile neutropenia was rare (3%) and other grade 3 / 4 toxicities all occurred 
in less than 5%.
A second trial, SWOG 99-16 was designed on the assumption that the combination 
of docetaxel and estramustine had the greatest therapeutic potential. Seven-hundred 
seventy patients were randomized to receive 280 mg estramustine three times daily 
on days 1-5, plus docetaxel 60 mg/m2 on day 2, preceded by 60 mg of dexamethasone 
divided in three doses, or  mitoxantrone 12 mg/m2  on day 1 plus 5 mg of prednisone 
twice daily [12]. Both were given in a 21-day cycle, and dose escalation to docetaxel 70 
mg/m2 or mitoxantrone 14 mg/m2 was allowed in cycle 2 if no grade 3/4 toxicities were 
observed during the first cycle. Median OS was superior in the group receiving docetaxel 
as compared to mitoxantrone (17.5 vs. 15.6 months respectively), with an HR of 0.80 
(95% CI 0.67-0.97). The group treated with docetaxel and estramustine had significantly 
higher rates of grade 3 and 4 neutropenic fever (5 percent vs. 2 percent), cardiovascular 
events (15 percent vs. 7 percent), and nausea and vomiting (20 percent vs. 5 percent), as 
compared with the group treated with mitoxantrone and prednisone.
Taken together, the results of these two phase III studies showed that docetaxel in a 
3-weekly regimen improved OS, which was the primary end point of both trials. Weekly 
docetaxel did not appear to be better tolerated than the 3-weekly regimen, and showed 
only a trend towards better efficacy. The SWOG study did not reveal greater benefit by 
the addition of estramustine. Because of the  lack of superior activity and greater toxicity 
by the addition of estramustine, docetaxel every 3 weeks plus low-dose prednisone 
subsequently became the standard of care for patients with mCRPC [14].
1
10
In multivariate analysis of TAX327, a total of ten independent prognostic factors 
for survival were identified  including the presence of liver metastases, number of 
metastatic sites, clinically significant pain,  Karnofsky performance status, type of 
progression,  pretreatment PSA doubling time, baseline PSA , tumor grade , baseline 
alkaline phosphatase, and  baseline hemoglobin [15].  These prognostic factors have been 
elaborated into a nomogram (Figure 2). Such decision making tools are informative, can 
facilitate tailoring of therapy, and can simplify important clinical decisions such as when 
to start cytotoxic chemotherapy. Although the survival benefit obtained by docetaxel 
compared with mitoxantrone is consistent among patients with and without pain at 
baseline (HR 0.73 and 0.85 respectively), there is a substantial difference in OS time (14.4 
months for patients with pain vs. 21.3 months for patients without pain). However, this 
does not necessarily imply benefit from the early use of chemotherapy, but may rather 
guide treatment in asymptomatic patients by defining patients at greater risk of imminent 
disease progression and death. These patients may be candidates for chemotherapy, even 
in the absence of symptoms. 
Figure 2 
Adapted from Armstrong A J et al. Clin Cancer Res 2007;13:6396-6403 (with permission) 
Permission CCR pending. 
©2007 by American Association for Cancer Research 
figure 2. Adapted from Armstrong A J et al. Clin Cancer Res 2007;13:6396-6403 (with permission)
Nomogram for survival of patients with progressive mCRPC, including data derived from 686 patients and 518 mortality events. 
Note: a prese t pai  int nsity of ≥2 and/or an analgesic score of ≥10 were defined in the original protocol as indicative of the 
presence of significant pain. Instructions for physician: Locate the liver metastasis axis. Draw a straight line upward to the points 
axis to determine how many points toward survival the patient receives for the presence or absence of liver metastases. Repeat 
this process for each predictor variable and sum the points for each predictor. Locate this sum on the total points axis. Draw a 
straight line downward from the total points axis to identify the predicted median survival and the predicted 1-, 2-, and 5-years 
predicted overall survival probabilities. Instructions to patient: “Mr. X, if we had 100 men exactly like you, we would expect 
<nomogram prediction × 100> to be alive in 1, 2, and 5 y, respectively, and we expect 50 of those to be alive after <median 
survival prediction> months.”
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Nonetheless, in the TAX327 study a decrease in quality of life was more often observed 
in patients with minimal symptoms at the start of chemotherapy [16]. Therefore delaying 
chemotherapy may be a suitable approach in patients with minimal symptoms. Those 
patients who have no symptoms yet, but are more likely to develop symptoms in the 
near future due to bone scan progression and/or the development of anemia should be 
considered candidates for docetaxel chemotherapy [14].
With the recent FDA and EMA approval of the CYP17 inhibiting agent abiraterone 
in the pre-docetaxel setting, it has become increasingly important to identify subgroups 
of patients who may have greater benefit by the use of chemotherapy in order to better 
tailor treatment choices. Recently, Azria et al. reported a high Gleason score [8-10] at the 
time of diagnosis to be an independent risk factor for poor response to abiraterone [17, 
18]. In addition, a retrospective analysis of patients with mCRPC enrolled in clinical trials 
demonstrated that patients who had a short response to prior androgen deprivation 
therapy (ADT) (<16 months), had poor PSA responses and PFS when treated with 
secondary hormonal therapies such as abiraterone, and enzalutamide [19]. In this light, 
a recent post-hoc analysis of the TAX327 study was conducted which revealed  that 
the survival benefit obtained with docetaxel as compared to mitoxantrone was most 
pronounced in patients with high Gleason score tumors (Gleason 7-10) [20]. Furthermore, 
two prospective databases of patients with mCRPC demonstrated similar PSA responses 
and clinical benefit obtained by docetaxel, irrespective of the duration of response to ADT [21]. 
In an era of shifting paradigms in mCRPC with abiraterone becoming available also 
prior to docetaxel chemotherapy, Gleason score and prior response to ADT may serve 
to discriminate between patients who benefit most from docetaxel chemotherapy as 
first-line treatment. Docetaxel, seems to exert efficacy particularly in high Gleason score 
tumors irrespective of response to ADT. In contrast, in patients with better differentiated 
tumors and durable responses to ADT abiraterone might be a good treatment option. 
In the future, these observations should be prospectively validated in order to further 
personalize first-line treatment options for patients with mCRPC.
Mechanism of action of taxanes: emerging data on ar transport as part of their 
efficacy
As mentioned above, docetaxel and cabazitaxel also impair AR signaling, which in the 
setting of mCRPC might in fact be responsible for part of the therapeutic efficacy [6-8]. 
Recently, clinical and preclinical evidence is emerging about potential cross-resistance 
between docetaxel and abiraterone [8]. A clinical report on patients treated with docetaxel 
who had previously been treated with abiraterone showed an OS of only 12.5 months, 
which was significantly less than the 19 months predicted for this patient population [22]. 
Moreover, PSA declines ≥50% were observed in 26% of patients, compared to 45% in the 
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TAX327 study [11], and no responses to docetaxel were observed in abiraterone-refractory 
patients. A likely explanation is that antitumor activity of taxanes in mCRPC is partly 
depending on its impact on AR-signaling. When patients are treated with abiraterone first, 
it could very well result in impaired effectiveness of docetaxel due to annulling its effects 
on the AR. Hence the sequence of abiraterone followed by docetaxel upon progression 
could result in decreased effectiveness of the chemotherapy and thus impair the eventual 
clinical benefit.
Cabazitaxel however seems to retain activity in the third-line setting following 
docetaxel and abiraterone, with ≥50% PSA declines in 42-49% of patients [23, 24]. 
Prospective clinical studies should further define the implications for the optimal 
treatment sequence of these treatment options for patients with mCRPC.
docetaxel retreatment
Sooner or later all patients will progress during or after treatment  with docetaxel. 
Patients who relapse after an initial response to docetaxel may again respond to a second 
or even third series of docetaxel cycles [25-27].  Since the phase II data on docetaxel 
rechallenge have been limited to efficacy , i.e.  PSA responses, pain responses and objective 
responses and data on survival benefit are lacking, such rechallenge has become a less 
likely choice following  the introduction of the new agents such as cabazitaxel, abiraterone 
and enzalutamide , which have all demonstrated survival benefit in patients relapsing 
after docetaxel chemotherapy [28-30].
An alternative approach to the standard of 10-12 cycles docetaxel as used in the 
pivotal phase III studies, is intermittent dosing of docetaxel suspending treatment after 6 
cycles or at a predefined PSA decrease, and retreatment when PSA starts to rise again. In 
one of the larger studies a majority of patients responded again to such retreatment [31]. 
These data are of particular interest because of the absence of a defined optimal duration 
of chemotherapy in responding cases with mCRPC [26, 32]. In a prospective phase II study, 
patients were enrolled who had responded to first-line docetaxel and progressed after a 
chemotherapy-free interval of at least 5 months.  Median overall survival since enrollment 
was 13 months, and a 50% PSA decline was observed in 24.5% of patients [25].  Like for 
docetaxel retreatment, OS data for intermittent docetaxel therapy are also lacking, and 
a second or series of docetaxel has become questionable due to the newly available 
systemic treatment options.
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docetaxel-based combination therapies
In the light of improved survival and modest toxicity with docetaxel as was 
demonstrated in TAX 327, numerous investigators, collaborative groups and industry have 
investigated whether the efficacy of docetaxel could be improved by adding a second 
agent [33]. Here we will discuss docetaxel combination studies. An overview of the phase 
III combination trials with docetaxel is shown in Table 1.
phase iii Trials
immunotherapy
The GVAX platform of immunotherapies involved injection of cells derived from 
prostate cancer cell lines to provoke an immune response to multiple antigens expressed 
by the tumor cell. In addition, the cells were modified to secrete granulocyte macrophage 
colony-stimulating factor (GM-CSF). The VITAL-2 trial compared GVAX plus 3-weekly 
docetaxel with docetaxel plus prednisone and was interrupted early due to an unexpected 
higher death rate in the GVAX arm (67 deaths for GVAX plus docetaxel vs. 47 deaths for 
docetaxel plus prednisone) [34]. Another trial (VITAL-1), compared GVAX with docetaxel 
in patients with asymptomatic CRPC [35]. The study was prematurely terminated based 
on the results of a futility analysis conducted by the study’s Independent Data Monitoring 
Committee (IDMC) which determined that the study had less than a 30% chance of 
meeting its predefined primary endpoint of improvement in overall survival.
Calcitriol
Calcitriol is an activated vitamin D analog that has shown to enhance antitumor 
activity of paclitaxel and docetaxel in vitro and in vivo [36, 37]. ASCENT-1 was a double-
blind randomized phase II study that investigated weekly docetaxel plus high-dose 
calcitriol versus docetaxel plus placebo [38]. The primary end-point PSA response rate 
did not differ between the treatment groups. Although it was not the primary end-point 
of the trial, there was an improvement in OS for calcitriol over the placebo group. The 
ASCENT-2 trial was a randomized phase III trial designed to validate the observed survival 
benefit obtained with docetaxel plus calcitriol in the ASCENT trial [39].  In the phase III 
trial the control arm comprised the standard docetaxel regimen every 3 weeks. At an 
interim analysis, more deaths were noted in the ASCENT arm and consequently the trial 
was terminated early. Median OS was 17.8 months (95% CI 16.0 to 19.5) for docetaxel plus 
calcitriol compared to 20.2 months (95% CI 18.8 to 23.0) for docetaxel plus prednisone. 
Reasons for the worse OS by docetaxel plus calcitriol arm may have been attributed to the 
use of the weekly docetaxel schedule in the investigational arm [39].
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endothelin-a receptor antagonists
Atrasentan is an endothelin-A receptor antagonist that enhanced the effects of 
docetaxel against prostate cancer cells in vitro and in vivo [40, 41]. In the SWOG S0421 
trial atrasentan plus docetaxel and prednisone was investigated in 991 patients with bone 
metastases. No difference in OS and PFS was observed for atrasentan plus docetaxel and 
prednisone compared with docetaxel and  prednisone alone  [42].  
Another endothelin A receptor antagonist zibotentan was investigated in the phase 
III trial ENTHUSE M1C combined with standard docetaxel versus docetaxel plus placebo. 
Docetaxel plus zibotentan did not result in a significant improvement in OS compared 
with docetaxel plus placebo (HR 1.00, 95%CI 0.84 – 1.18) [43].
angiogenesis inhibitors
The oral angiogenesis inhibitor thalidomide demonstrated additive effects to taxane 
chemotherapy in vitro [44]. In two randomized phase II trials, the addition of thalidomide 
to docetaxel resulted in an encouraging PSA decline rates. Although more tromboembolic 
events were observed in patients treated with thalidomide, the combination regimen 
was reported to be well tolerated after the administration of prophylactic low-molecular-
weight heparin [45, 46]. Lenalidomide is the successor of thalidomide with greater anti-
angiogenesis efficacy as well as imunomodulatory effects. The randomized phase III 
trial (MAINSAIL) evaluated the efficacy of lenalidomide plus docetaxel versus docetaxel 
and placebo as first-line treatment for mCRPC. Following an interim analysis the study 
was stopped due to greater toxicity in the investigational arm and possibly reduced 
effectiveness. This could have been due to more frequent docetaxel dose reductions in 
patients allocated to lenalidomide [47].
Bevacizumab is a humanized immunoglobulin G monoclonal antibody to all the 
isoforms of VEGF-A. The CALBG Group investigated the addition of bevacizumab to 
standard docetaxel and prednisone in a randomized phase III trial. Despite an improvement 
in PFS and objective response, the addition of bevacizumab to docetaxel and prednisone 
did not improve OS and was associated with greater toxicity [48].
Aflibercept, a recombinant human fusion protein that binds A and B isoforms of VEGF 
and placental growth factor thereby inhibiting angiogenesis, was investigated  in the 
phase III VENICE trial. In this study 1224 men were treated with docetaxel plus prednisone 
and randomized to receive aflibercept or placebo. Median overall survival was 22.1 
months (95.6% CI 20.3-24.1) in the aflibercept group and 21.2 months (95.6% CI 19.6-
23.8) in the placebo group (stratified hazard ratio 0.94; 95.6% CI 0.82-1.08; p=0.38). The 
combination of aflibercept and docetaxel was associated with a  higher incidence of grade 
3/4 gastrointestinal disorders, hemorrhagic events, hypertension, fatigue, infections, and 
treatment related fatal adverse events [49].
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Bone microenvironment agents
SRC-family kinases play an important role in prostate cancer growth and invasion, as 
well as the pathogenesis of bone metastases and the regulation of osteoclast function 
[50-52]. Among others, dasatinib  potently inhibits the SRC family kinases (SRC, LCK, 
HCK, FYN, YES, FGR, BLK, LYN, and FRK [53]. In preclinical studies the tyrosine kinase 
inhibitor  dasatinib  inhibited cell duplication, migration, and invasion, and triggered 
apoptosis of tumoral cells.  Dasatinib  also acts on the tumor microenvironment, which 
is particularly important in the bone, where  it  inhibits osteoclastic activity and favors 
osteogenesis, exerting a bone-protecting effect [53]. These preclinical studies led to the 
hypothesis that combining dasatinib with docetaxel would improve treatment outcomes 
by targeting both the tumor and bone microenvironment. In a phase I/II study combining 
docetaxel with dasatinib, 18 out of 30 patients with measurable disease had a partial 
response and 14 patients had disappearance of lesions on bone scans [54]. However, 
the phase III READY trial demonstrated no survival benefit for docetaxel plus dasatinib 
compared to docetaxel and placebo [55].
Custirsen
Clusterin (CLU) is a stress-activated cytoprotective chaperone upregulated by a 
variety of anticancer therapies that lends treatment resistance when overexpressed 
[56]. Preclinical studies have shown that knockdown of clusterin enhances the effects 
of docetaxel in docetaxel-refractory cells [57]. A randomized phase II trial investigated 
custirsen (OGX-11), an antisense inhibitor of clusterin, in combination with docetaxel 
and prednisone, versus docetaxel and prednisone alone. The combination of docetaxel 
and prednisone with OGX-11 was associated with a longer median OS, despite similar 
rates of PSA and tumor response [58]. Two phase III trials of OGX-11 in first- and second 
line treatment of mCRPC are currently underway. Due to its unique mechanism of action, 
these trials are the only ongoing phase III studies with the potential of having a positive 
outcome in terms of survival benefit. 
1
16
Table 1. Phase III trials of docetaxel-based combinations
Agent Result
Docetaxel + GVAX OS inferior in combination arm: 12.2 vs. 14.1 months
 (VITAL-2) HR 1.70 (95% CI 1.15-2.53)
Docetaxel + Calcitriol OS inferior in combination arm: 17.8 vs. 20.2 months
(ASCENT-2) HR 1.42 (95% CI 1.13-1.86)
Docetaxel + Atrasentan OS not improved in combination arm: 18 vs. 17 months
(SWOG S0421) HR 1.01 (95% CI 0.87-1.18)
Docetaxel + Zibotentan OS not improved in combination arm: 20 vs. 19.2 months
(ENTHUSE M1C) HR 1.00 (95% CI 0.84-1.18)
Docetaxel + Lenalidomide OS inferior in combination arm: 17.7  vs.  median not reached
(MAINSAIL) HR 1.53 (95% CI 1.17-2.00)
Docetaxel + Bevacizumab OS not improved in combination arm: 22.6 vs. 21.5 months
(CALBG 90401) HR 0.91 (95% CI 0.78-1.05)
Docetaxel + Aflibercept OS not improved in combination arm: 22.1 vs. 21.2 months
(VENICE) HR 0.94 (95.6% CI 0.82-1.08)
Docetaxel + Dasatinib OS not improved in combination arm: 21.5 vs. 21.2 months
(READY) HR 0.99 (95% CI 0.87-1.13)
Docetaxel + Custirsen
Ongoing
(SYNERGY)
phase ii Trials
The addition of bcl-2 inhibitor AT-101 in combination with docetaxel was evaluated 
in a phase II trial with OS as the primary endpoint. The addition of AT-101 did not extend 
OS, PFS or PSA response as compared with docetaxel and prednisone [59]. The bcl-2 
antisense oligonucleotide oblimersen was combined with docetaxel in an EORTC phase 
II trial. Primary endpoints including a rate of confirmed PSA response >30% and a major 
toxic event rate <45% were not reached [60].
In a randomized phase II trial of docetaxel and vandetanib, an oral inhibitor of vascular 
endotherlial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR), 
no benefit was reported for the combination compared to docetaxel and placebo [61]. A 
single arm phase I/II trial of docetaxel plus sunitinib, an inhibitor of VEGFR and platelet 
derived growth factor (PDGFR) demonstrated PSA responses in 56.4% of patients [62]. In 
another single-arm phase II trial evaluating sorafenib and docetaxel PSA responses were 
observed in 46% of patients [63]. 
The PDGFR inhibitor imatinib was also investigated in combination with weekly 
docetaxel in a phase II trial. Increased adverse gastrointestinal events were observed in 
the experimental arm. These events coupled with a futility analysis which indicated that a 
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significant treatment difference would be unlikely for the planned accrual of 144 patients, 
led to early termination of the study [64].  
None of these agents is currently under investigation in a phase III clinical trial.
In summary, docetaxel plus prednisone remains the gold standard of chemotherapy. 
None of the eight phase III docetaxel based combination trials have demonstrated 
a survival benefit when compared with the standard docetaxel regimen. A critical 
assessment by Antonarakis and Eisenberger of the phase II trials that led to the initiation 
of these studies  showed that the results might not have been sufficient for the conduction 
of large phase III studies. Either no phase II data were available, or the metric for success 
that would prompt phase III development was not defined or reached [65]. 
CaBaziTaxel
Cabazitaxel was selected from 450 taxane derivatives, based on its antitumor activity in 
docetaxel-resistant tumor models [5]. Unlike the other taxanes (paclitaxel and docetaxel), 
cabazitaxel has poor affinity for the drug transporter p-glycoprotein (P-gp, ABCB1) [66, 67]. 
An additional characteristic of cabazitaxel is its ability to penetrate the blood-brain barrier 
in vivo, which is limited with other taxanes [68]. Recently it has been demonstrated that 
cabazitaxel also inhibits AR nuclear translocation, which could be an additional mechanism 
of taxane anti-tumor activity in mCRPC [8].
A phase I trial in patients with solid tumors determined that cabazitaxel had 
linear pharmacokinetics similar to docetaxel, but probably better tolerability [66]. The 
principal dose-limiting toxicity was neutropenia, with one patient experiencing febrile 
neutropenia and two others showing prolonged grade 4 neutropenia at the 25 mg/m2 
dose level. Non-hematologic toxicities included nausea, vomiting, diarrhea, neurotoxicity, 
and fatigue, and were generally mild to moderate. Objective antitumor activity was 
observed in two  patients with partial responses including one patient with docetaxel-
refractory mCRPC. One patient had an unconfirmed partial response, and two patients 
had minor responses. Subsequently, two proof of principle trials were conducted which 
demonstrated responses in patients with taxane resistant metastatic breast cancer [67, 69]. 
The Phase III TROPIC trial was a randomized, open-label, multicenter trial, conducted in 755 
men with mCRPC who progressed during or after docetaxel chemotherapy [29]. Patients 
were randomized to receive either cabazitaxel 25 mg/m2 or mitoxantrone 12 mg/m2 in a 
3 weekly regimen, each with 10 mg prednisone daily. Median OS was 15.1 months for the 
cabazitaxel arm versus 12.7 months in the mitoxantrone arm, with a hazard ratio (HR) for 
death of 0.70 (95% CI 0.59-0.83, p<0.0001). Secondary endpoints including progression 
free survival, PSA response, objective tumor response according to RECIST criteria, time 
to PSA progression and median time to tumor progression were all significantly improved 
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in the cabazitaxel arm. Pain response rates were similar between the two treatment arms. 
About 70% of patients had progressive disease during or within 3 months after docetaxel 
treatment, including about 30% of patients who had disease progression during docetaxel 
treatment. The benefit of cabazitaxel as compared to mitoxantrone was consistent among 
subgroups of patients defined by prognostic factors including patients with disease 
progression during docetaxel treatment and in those who received high cumulative 
doses of docetaxel.
In concordance with the TAX327 trial, a post-hoc analysis of the TROPIC trial linked 
a significant OS benefit for cabazitaxel versus mitoxantrone to patients with poorly 
differentiated tumors evaluated by WHO grade (median OS 15.2 months vs 12.7 months, 
p<0.0001), whereas for patients with well or moderately differentiated tumors this 
benefit was less robust, with a median OS of 15.5 months for cabazitaxel and 13.3 months 
for mitoxantrone (p=0.56) [70].  In this post-hoc analysis, the OS benefit obtained by 
cabazitaxel was independent of the duration of ADT. In contrast, a high Gleason score 
(Gleason 8-10) and a short response to prior ADT (≤16 months) may be predictive of a 
poor PSA response and PFS in patients treated with abriraterone [17, 19]. These easily 
available parameters could be of value in determining which treatment, cabazitaxel , or 
an agent like abiraterone has the greatest therapeutic potential in an individual patient as 
second-line treatment for mCRPC.
Patients received a median of 6 cycles for cabazitaxel, and 4 cycles for mitoxantrone. 
The most frequent hematological AE’s were hematologic. Grade ≥3 neutropenia was 
more common in patients who received cabazitaxel (82%) than in patients who received 
mitoxantrone (58%), with febrile neutropenia rates of 8% and 1% respectively. The most 
frequent non-hematologic AE was diarrhea, occurring in 47% (grade ≥3, 6%) of patients 
treated with cabazitaxel, compared to 11% (grade ≥3, <1%) of patients treated with 
mitoxantrone.
A total of 18 patients (4.9%) who were treated with cabazitaxel died from causes 
other than disease progression within 30 days of receiving their last dose of cabazitaxel. 
This compares with 3 drug-related patient deaths (0.9%) in the mitoxantrone group. 
The most common cause of death in patients who were treated with cabazitaxel was 
neutropenia and its clinical consequences. However, no further deaths due to neutropenic 
complications occurred in the cabazitaxel group following the IDMC communication 
to the TROPIC investigators about the need to strictly adhere to the study protocol 
regarding dose delays and modifications and to manage neutropenia with granulocyte 
colony-stimulating factor (G-CSF) according to American Society for Clinical Oncology 
(ASCO) guidelines. The frequency of hematological adverse events and related deaths 
demonstrates that cabazitaxel treatment requires careful monitoring and management 
of emerging symptoms. Dose reductions as well as the administration of granulocyte 
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colony-stimulating factor (G-CSF) according to ASCO guidelines are strategies that should 
be considered in patients with high risk clinical features (age ≥65 years, poor performance 
status, previous episodes of febrile neutropenia, extensive prior radiation ports, poor 
nutritional status, or other serious comorbidities) to manage side effects of treatment 
with cabazitaxel. In an attempt to reduce cabazitaxel induced toxicity, an open-label 
randomized phase II study is currently testing whether the addition of the oral poorly 
resorbable steroid budesonide reduces or protects against cabazitaxel induced diarrhea.
 FIRSTANA is a randomized phase III trial with OS as the primary endpoint comparing 
cabazitaxel 25mg/m2 and cabazitaxel 20mg/m2 both with prednisone, to docetaxel 75 
mg/m2 plus prednisone as first-line treatment for mCRPC. PROSELICA is an ongoing trial 
with a non-inferiority design comparing cabazitaxel 25mg/m2  to cabazitaxel 20mg/m2 
both with prednisone. These studies will answer the questions whether a reduced dose 
of cabazitaxel may provide similar OS with the benefit of reduced toxicity, and whether 
cabazitaxel has greater therapeutic potential compared to docetaxel as first-line treatment 
for mCRPC.
At the present time, cabazitaxel has demonstrated survival benefit in patients 
progressing during or after treatment with docetaxel. In the Phase III TROPIC trial, the 
OS benefit obtained was consistent among the two thirds of patients enrolled who 
had either disease progression during docetaxel (29%) or within 3 months after the last 
docetaxel cycle (45%).  Cabazitaxel has thus a different mode of action and is an important 
contribution to the management of patients with mCRPC who have failed docetaxel 
chemotherapy.
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CHAPTeR 2
iNTRoduCTioN To THe THesis
inTroduCTion To The Thesis
Prostate cancer is the most commonly diagnosed cancer and the sixth leading cause 
of cancer-related death among men in the Western world [1]. This disease is characterized 
by a heterogeneous natural history, with a considerable number of patients who will 
never develop symptoms, and will not die from prostate cancer. When prostate cancer 
is still organ confined, treatment options include radical surgery, radiotherapy with or 
without hormonal therapy, brachytherapy, and active surveillance. Despite an abundance 
of local therapies, a significant proportion of patients will eventually develop metastases 
from prostate cancer. Patients with metastatic prostate cancer cannot be cured and have 
a high likelihood of ultimately dying from their disease. 
Androgen receptor (AR)-targeted therapy has been the mainstay of treatment for 
metastatic prostate cancer since the first description of the hormonal dependence of this 
cancer in 1941 [2]. Since prostate cancer cells are generally dependent on AR signaling 
for growth and survival,  patients with metastatic prostate cancer initially respond well 
to either medical or surgical castration, with or without the addition of anti-androgens. 
However, eventually all patients will progress and develop castration-resistant prostate 
cancer (CRPC). Castration-resistant prostate cancer is defined by either PSA or radiological 
progression, despite castrate levels of testosterone (<50 ng/dl) [3]. 
Taxanes (i.e. docetaxel and cabazitaxel) inhibit microtubule dynamics, thereby 
inducing cell death and apoptosis [4, 5]. For almost a decade, docetaxel chemotherapy has 
been the standard of care in the management of metastatic castration-resistant prostate 
cancer (mCRPC), following reports of improvement in survival and quality of life in the 
pivotal TAX327 and SWOG 99-16 studies [6, 7] (Chapter 1). For regulatory purposes, after 
the approval of docetaxel in 2004 all new drugs for mCRPC were investigated in either the 
pre- or post-docetaxel space. In 2010, the novel taxane cabazitaxel became approved for 
the treatment of mCRPC in patients who progressed during or after docetaxel. This was 
based on a survival benefit of cabazitaxel plus prednisone as compared with mitoxantrone 
plus prednisone observed in men with disease progression during or after docetaxel in 
the TROPIC trial [8]. 
In recent years, it has become clear from the biology of mCRPC that the AR remains an 
important driver of mCRPC. This was evidenced by the survival benefits and subsequent 
regulatory approval of abiraterone and enzalutamide in the post-docetaxel setting [9, 
10]. Abiraterone targets the AR indirectly by inhibiting CYP17A1, a crucial enzyme in 
steroidogenesis, and enzalutamide directly binds to the AR ligand binding domain, 
inhibiting multiple steps in the AR signaling pathway [11, 12]. Recently, the treatment 
paradigm has shifted with evidence that these novel AR targeted agents are also effective 
when administered to men with mCRPC before chemotherapy [13, 14]. With these novel AR 
targeting therapies now also available in the pre-chemotherapy setting, treatment choices 
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and drug sequencing for patients with mCRPC has become increasingly challenging. 
First, the optimal drug treatment sequence for patients is unknown. Emerging 
retrospective evidence has suggested that some of the currently available therapies 
might be cross-resistant [15, 16], a condition in which sensitivity to one drug is impaired 
by previous treatment with another drug having a similar or overlapping mechanism 
of action. Therefore, defining mechanisms of cross-resistance between the currently 
available treatment options in mCRPC is of utmost importance to unravel the optimal 
treatment sequence for our patients.
Second, predictive biomarkers defining which patients will benefit from the available 
therapies are lacking. Such markers are urgently needed by clinicians to guide treatment 
choices for an individual patient, in order to better tailor therapy. This will ultimately define 
which patients will benefit from which treatment, and could help to avoid unnecessary 
treatment, and improve quality of life by limiting drug-related toxicity. 
In this thesis, we investigated mechanisms of cross-resistance between taxanes and 
new hormonal agents abiraterone and enzalutamide. Furthermore, we aimed to identify 
both predictive and prognostic factors for patients with mCRPC receiving docetaxel 
chemotherapy.
In chapter 3 we used patient-derived CRPC cell lines to identify and give insight 
in mechanisms of cross-resistance between docetaxel, cabazitaxel, abiraterone and 
enzalutamide, all four drugs registered for the treatment of mCRPC. AR-nuclear 
translocation was studied as an overlapping working mechanism between these drugs, 
and thus a potential mechanism of cross-resistance.
In chapter 4 we confirmed our previous in vitro findings of cross-resistance between 
docetaxel and enzalutamide in an in vivo model of CRPC. Mechanisms of cross-resistance 
were further elucidated by exploring the role of the AR pathway in enzalutamide-resistant 
versus enzalutamide-naïve xenografts, treated with docetaxel and cabazitaxel. The 
hypothesized superior efficacy of cabazitaxel over docetaxel was also evaluated in this in 
vivo model of CRPC.
In chapter 5 we aimed to clinically confirm our findings from the in vivo study from 
chapter 4. For this purpose, we investigated whether the efficacy of cabazitaxel in mCRPC 
patients was affected by prior treatment with abiraterone and enzalutamide. We used 
data from a prospective, multicenter, randomized phase II trial (CABARESC) to compare 
clinical outcome of patients treated with cabazitaxel with and without prior treatment 
with abiraterone and/or enzalutamide.
In chapter 6 we aimed to identify subgroups of patients who benefit the most from 
docetaxel chemotherapy. Since it had been hypothesized that taxane chemotherapy 
is particularly effective in rapidly proliferating, undifferentiated tumors [17-19], we 
performed a post-hoc analysis of the pivotal TAX327 study to investigate the benefit 
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obtained by docetaxel according to the initial biopsy Gleason score.
An emerging biomarker across different tumor types and disease settings is the 
neutrophil to lymphocyte ratio (NLR). An elevated NLR, a marker for host inflammation, 
was found to be an independent marker of adverse outcomes for several solid tumors 
including mCRPC [20]. In men with mCRPC treated with abiraterone, NLR ≥5 was 
associated with lower PSA response rates and shorter survival [21]. In chapter 7 we 
explored the prognostic and predictive role of the neutrophil to lymphocyte ratio (NLR) 
in two multinational randomized phase III trials of mCRPC patients receiving first-line 
chemotherapy. 
Finally, the results of this thesis are discussed and suggestions for further research 
are mentioned (chapter 8). In summary, this thesis investigated mechanisms of cross-
resistance between the currently available treatment options for mCRPC in order to define 
the optimal treatment sequence. Furthermore, several predictive and prognostic factors 
in patients receiving first-line chemotherapy were explored. With this studies, we hope to 
ultimately contribute to unraveling the drug treatment sequence with the most benefit 
for our patients.
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CHAPTeR 3
aBsTraCT
introduction: Treatment options for patients with metastatic castration-resistant prostate 
cancer (mCRPC) have expanded in recent years with the introduction of cabazitaxel, 
abiraterone, and enzalutamide. With new systemic therapies available, the optimal 
treatment sequence of these drugs in mCRPC becomes increasingly important. As shown 
recently, patients who had previously been treated with abiraterone showed impaired 
responses to docetaxel, suggesting clinical cross-resistance.1 In the present study, we 
aimed to identify cross-resistance between taxanes (docetaxel and cabazitaxel) and the 
new hormonal agents abiraterone and enzalutamide. As a potential mechanism for cross-
resistance, we investigated the effects on androgen receptor (AR) nuclear translocation of 
these compounds.
Methods: To identify cross-resistance, we determined the effects of docetaxel, cabazitaxel, 
abiraterone and enzalutamide on cell viability in prostate cancer cell lines with acquired 
resistance to abiraterone and enzalutamide. Time-lapse confocal microscopy was used to 
study the dynamics of AR nuclear translocation.
results:  We observed impaired efficacy of docetaxel, cabazitaxel, and enzalutamide in the 
abiraterone-resistant cell line, compared to the non-resistant cell line, providing evidence 
for in vitro cross-resistance. Impaired efficacy of docetaxel, cabazitaxel and abiraterone 
was observed in the enzalutamide-resistant cell line. Furthermore, docetaxel and 
cabazitaxel inhibited AR nuclear translocation, which was also observed for abiraterone 
and enzalutamide.
Conclusions: In conclusion we found substantial preclinical evidence for cross-resistance 
between the taxanes docetaxel and cabazitaxel, and AR targeting agents abiraterone 
and enzalutamide. Since these compounds all interfere with AR signaling, this strongly 
suggests a common mechanism of action, and thus a potential mechanism for cross-
resistance in mCRPC. 
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inTroduCTion
Prostate cancer cells are dependent on androgen receptor (AR) signaling for growth 
and survival. Therefore, patients with metastatic prostate cancer initially respond well 
to luteinizing hormone releasing hormone (LHRH) analogues or surgical castration, 
with or without anti-androgens. However, eventually all patients develop castration-
resistant prostate cancer. Docetaxel is the standard first line chemotherapy for metastatic 
castration-resistant prostate cancer (mCRPC) and has shown survival benefit as well 
as palliative benefit in phase III clinical trials [2, 3]. For patients who progress after 
docetaxel chemotherapy several new treatment options have become available recently. 
Cabazitaxel and AR targeting agents abiraterone and enzalutamide all demonstrated 
improved overall survival (OS) in patients with mCRPC who progressed after docetaxel-
based chemotherapy [4-6]. Taxanes (i.e. paclitaxel, docetaxel, and cabazitaxel) act through 
microtubule interaction and polymerization inducing mitotic arrest and apoptosis. 
Recent reports demonstrated that paclitaxel and docetaxel also impair AR-signaling, 
which in the setting of mCRPC might in fact be responsible for part of the therapeutic 
efficacy [7, 8]. AR-signaling remains an important target for therapy in mCRPC, which has 
been demonstrated by the survival benefit obtained by abiraterone and enzalutamide. 
Enzalutamide exerts its effect by inhibiting AR nuclear translocation, DNA-binding and 
co-activator recruitment [9]. Abiraterone inhibits androgen biosynthesis by irreversibly 
blocking CYP17A1, a crucial enzyme in steroidogenesis [10, 11].  
Recently abiraterone has shown improved radiographic progression-free survival 
(PFS) and a trend towards improved OS in chemotherapy-naive patients [12]. Based on 
this trial, the US Federal Food and Drug Administration (FDA) and the European Medicines 
Agency (EMA) lent approval to the use of abiraterone in patients with mCRPC prior to 
docetaxel chemotherapy. With new therapies available in the pre-docetaxel setting, the 
challenge has become to determine the treatment sequence which yields the greatest 
survival benefit for patients with mCRPC. In this light, it was reported that the activity 
of docetaxel post-abiraterone appeared lower than anticipated, with a median OS of 
only 12.5 months, which was less than the 19 months observed in the TAX327 trial [1, 
2]. Moreover, fewer patients had a ≥ 50% PSA response (26%) as compared to a similar 
abiraterone-naïve patient cohort (54%), and compared to TAX327 (48%). No PSA responses 
to docetaxel were observed in patients who did not have a PSA response on abiraterone 
either.
Likewise, the activity of abiraterone appears to be higher when used before 
chemotherapy than in patients who have been previously exposed to docetaxel. In two 
phase II trials with abiraterone, a ≥50% PSA decline was observed in 67% and 79% of 
chemotherapy-naive patients, respectively, compared to 29% in the post-chemotherapy 
COU-AA-301 phase III trial [6, 13, 14]. In addition, a ≥50% PSA decline was observed in 62% 
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of patients in the randomized phase III trial of abiraterone pre-chemotherapy [12].
Taken together, these data may be explained by cross-resistance, a condition in 
which sensitivity to one compound is impaired by another compound with a similar or 
overlapping mechanism of action. In this report, we describe preclinical evidence for 
cross-resistance between the taxanes docetaxel and cabazitaxel and new hormonal 
agents abiraterone and enzalutamide, all four drugs currently registered for the use in 
mCRPC. Furthermore, as a potential mechanism for cross-resistance, we investigated the 
effects of these compounds on AR nuclear translocation. 
MaTerials and MeThods
Cell lines 
The PC346C human prostate cancer cell line was derived and maintained as described 
previously [15-17]. Briefly, cells were cultured in special Prostate Growth Medium (PGM) 
based on DMEM-F12 medium with several prostate cancer growth factors [15], 100 U/
ml Penicillin, and 100 μg/ml Streptomycin (Cambrex BioWhittaker, Verviers, Belgium), 
supplemented with 2% FCS (PAN Biotech, Aidenbach, Germany) and 0.1 nM of the 
synthetic androgen R1881 (NEN, Boston, MA). The PC346Abi101 and PC346Enza cell lines 
were generated by continuous culturing of PC346C cells in PGM medium supplemented 
with 2% dextran-coated charcoal stripped serum (DCC), with the addition of 1μM 
abiraterone for PC346Abi101 and 1μM enzalutamide for PC346Enza. After initial cell death, 
resistant cells started to grow out under the selection conditions used. PC346C cells stably 
expressing GFP labeled AR (GFP-AR) were generated using lentiviral transduction. For the 
experiments, cells were cultured in the same DCC-containing PGM medium [15].
The Hep3B cell lines stably expressing GFP-AR and YFP-b-tubulin were generated and 
maintained as described previously [18, 19]. The YFP-b-tubulin expression construct was 
kindly provided by Dr. Galjart (Erasmus University Medical Center). 
Confocal microscopy
For confocal microscopy, Hep3B GFP-AR, Hep3B YFP-b-tubulin, and PC346C GFP-AR 
cells were seeded on a glass cover slip and cultured in DCC-containing medium.  After 
overnight attachment, cells were treated with docetaxel (1 µM) [8, 20], cabazitaxel (1 
µM), mitoxantrone (100 nM), abiraterone (6 µM) [21, 22]_ENREF_21, and enzalutamide 
(1 µM). Incubation times were 48 hours and 4 hours for Hep3B GFP-AR and PC346C GFP-
AR cells respectively. Docetaxel and cabazitaxel were kindly provided by Sanofi (Paris, 
France). Abiraterone and enzalutamide were obtained from Sequoia Research Products 
(Pangbourne, UK). Mitoxantrone was obtained from EMD Serono (Rockland, MA). Confocal 
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microscopy was performed on a Zeiss LSM510 microscope (Carl Zeiss, Jena, Germany) 
equipped with a 63×/1.3 NA oil immersion objective using the 488 nm (GFP-AR) and 514 
nm (YFP-b-tubulin) laser line of a 200 mW Ar laser. Cells were transferred to a live-cell 
chamber and maintained at 37°C and 5% CO2. For time-lapse imaging, images of Hep3B 
GFP-AR cells were acquired every 5 minutes during 130 minutes at multiple locations of 
the same sample. After 10 minutes of imaging, 1 nM of the synthetic androgen R1881 was 
added to the medium to induce AR nuclear translocation. Average fluorescence intensities 
in the nucleus and cytoplasm were measured at each time point using Image J software 
(RSB, NIH, Bethesda, MD). The percentage of AR nuclear localization was expressed as: 
nuclear signal intensity / (nuclear signal intensity + cytoplasmatic signal intensity) x 100, 
after background subtraction. The mean percentage of AR nuclear localization of 18-28 
cells in three independent experiments ± SEM was plotted for the treatment conditions 
at every time point. 
MTT proliferation assays
To determine the effects of docetaxel, cabazitaxel, abiraterone, enzalutamide and 
mitoxantrone on cell viability, we used an assay based on the enzymatic reduction of 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich, 
St.Louis, MO) by metabolically active cells as described previously [23]. Briefly, cells 
were seeded in 96-well dishes at 5,000 cells per well in DCC medium. After overnight 
attachment, PC346C, PC346Abi101 and PC346Enza cells were incubated for 10 days with 
docetaxel, cabazitaxel, abiraterone, enzalutamide, mitoxantrone, or vehicle at indicated 
concentrations, with the addition of 0.1 nM R1881. Hep3B GFP-AR cells were incubated 
for 48 hours with the same compounds.  Four replicates per condition were used. Data are 
expressed mean ± SEM of 3 independent experiments. IC50 values were calculated in Prism 
GraphPad 5.0 using the following formula: Y=100/(1+10^(X-LogIC50)). To statistically test 
differences in IC50 values between cell lines we used the extra sum-of-squares F test with 
a boundary for significance of p<0.01.
resulTs
docetaxel and cabazitaxel efficacy is impaired in pC346abi101and pC346enza cells
To identify cross-resistance between docetaxel and cabazitaxel, and the hormonal 
agents abiraterone and enzalutamide, we investigated the effects of docetaxel and 
cabazitaxel on cell viability in PC346Abi101 and PC346Enza cells, in which acquired resistance 
to abiraterone (PC346Abi101) and enzalutamide (PC346Enza) was developed in vitro (Fig. 1 A 
and Fig. 2 A). Protein expression of AR and PSA for PC346C, PC346Abi101, and PC346Enza was 
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determined using Western blotting and is shown in Supplementary Fig. S1. 
We observed that docetaxel and cabazitaxel efficacy was significantly impaired in 
both PC346Abi101 and PC346Enza cells, as compared to the parental PC346C cells (Fig. 1 
B, C and Fig. 2 B, C), suggesting cross-resistance between both taxanes and abiraterone, 
as well as both taxanes and enzalutamide. To determine whether the observed cross-
resistance was specific for the microtubule-targeting agents docetaxel and cabazitaxel, 
we used mitoxantrone as a control cytotoxic agent that does not target microtubules. 
Mitoxantrone efficacy was not significantly impaired in PC346Abi101 and PC346Enza 
cells, showing similar efficacy as in PC346C cells (Fig. 1 D and Fig. 2 D). IC50 values for the 
various compounds in PC346Abi101 and PC346Enza versus PC346C are shown in Table 1.
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figure 1. Docetaxel, cabazitaxel, and enzalutamide efficacy is impaired in PC346Abi101 cells, in which resistance to abiraterone 
was acquired by continuous culturing in the presence of 1 µM abiraterone. Cell viability of PC346Abi101 and PC346C cells is 
shown after 10 days of incubation with abiraterone (A), docetaxel (B), cabazitaxel (C), mitoxantrone (D), and enzalutamide (E) at 
indicated concentrations. Cell viability was assessed by MTT-assay. Four replicates per condition were used. Data are expressed 
as mean ± SEM of 3 independent experiments. 
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figure 2. Docetaxel, cabazitaxel, and abiraterone efficacy is impaired in PC346Enza cells, in which resistance to enzalutamide 
was acquired by continuous culturing in the presence of 1 µM enzalutamide. Cell viability of PC346Enza and PC346C cells is 
shown after 10 days of incubation with enzalutamide (A), docetaxel (B), cabazitaxel (C), mitoxantrone (D), and abiraterone (E) at 
indicated concentrations. Cell viability was assessed by MTT-assay. Four replicates per condition were used. Data are expressed 
as mean ± SEM of 3 independent experiments. 
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Table 1. IC50 values for abiraterone, docetaxel, cabazitaxel, mitoxantrone and 
enzalutamide in PC346C versus PC346Abi101 and PC346Enza
Cell line 
Compound:
pC346C pC346abi101 pC346enza 
 iC50 (95% Ci)  iC50 (95% Ci) iC50 (95% Ci)
Abiraterone (µM) 0.6 (0.5-0.8) 19.3 (15.1-24.8)* 12.2 (9.4-15.9)*
Docetaxel (nM) 0.3 (0.2-0.5) 9.3 (4.5-19.4)* 23.9 (13.6-42.0)*
Cabazitaxel (nM) 0.2 (0.1-0.5) 24.1 (11.4-51.0)* 7.2 (3.6-14.4)*
Mitoxantrone (µM) 0.2 (0.1-0.5) 0.5 (0.2-1.1) 0.05 (0.02-0.1)
Enzalutamide (µM) 3.3 (2.4-4.6) 26.6 (12.3-57.4)* 102.7 (35.7-295.8)*
*IC50 Significantly higher as compared to IC50 PC346C (p<0.01)
abiraterone and enzalutamide efficacy is impaired in pC346enza and pC346abi101 
cells
To investigate cross-resistance between the AR targeting agents abiraterone and 
enzalutamide, we determined the efficacy of abiraterone in the enzalutamide-resistant 
cell line PC346Enza, and the efficacy of enzalutamide in the abiraterone-resistant cell line 
PC346Abi101. We observed strongly impaired efficacy of enzalutamide in PC346Abi101 
cells as compared to PC346C (Fig. 1 E). Likewise, the efficacy of abiraterone was diminished 
in PC346Enza as compared to PC346C, which suggests cross-resistance between these 
two hormonal agents (Fig. 2 E). 
docetaxel, cabazitaxel, abiraterone and enzalutamide inhibit r1881 induced ar 
nuclear translocation.
To investigate the dynamics of AR nuclear translocation, time-lapse microscopy was 
used to determine AR nuclear localization at regular time intervals after addition of R1881 
in Hep3B GFP-AR cells pretreated for 48 hours with docetaxel, cabazitaxel, abiraterone, 
enzalutamide, and mitoxantrone (Fig. 3 A and B). Pretreatment of cells with docetaxel and 
cabazitaxel inhibited AR nuclear translocation with 21% and 34% respectively compared 
to vehicle control. We investigated mitoxantrone as a control to determine whether this 
effect could be linked to the interference of microtubule dynamics by docetaxel and 
cabazitaxel. As expected, mitoxantrone pretreatment did not cause an impairment of AR-
translocation to the nucleus. Together with the observation that docetaxel and cabazitaxel 
clearly affected microtubules after 48 hours of treatment this strengthens the hypothesis 
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that microtubules may at least partly facilitate AR transport (Fig. 3 C). The reduced AR 
translocation after pretreatment with docetaxel and cabazitaxel for 48 hours could not 
be explained by cytotoxic effects, since neither of these compounds showed evidence of 
cellular toxicity under these conditions (Supplementary Fig. S2 A) and overall cell viability 
had even increased compared to day 0 (Supplementary Fig. S2 B). 
Pretreatment of Hep3B GFP-AR cells with abiraterone inhibited AR nuclear 
translocation with 58% as compared to control. This observation demonstrates that 
besides inhibiting CYP17A1, abiraterone can act as an anti-androgen in the presence of 
R1881. As expected, no AR nuclear import was observed in enzalutamide treated cells 
after the addition of R1881. Cell viability of the cells was not affected by abiraterone and 
enzalutamide (Supplementary Fig. S2 C and D).
We confirmed our observations from the Hep3B GFP-AR cells in a prostate cancer 
specific model using PC346C cells stably expressing GFP-AR. Fig. 4 demonstrates 
that docetaxel and cabazitaxel, as well as abiraterone and enzalutamide inhibited 
R1881 induced AR nuclear transport in these cells as compared to vehicle control and 
mitoxantrone. 3
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figure 3. Docetaxel, cabazitaxel, abiraterone and enzalutamide inhibit AR nuclear import. Hep3B cells expressing GFP-AR were 
pre-treated with docetaxel (1 µM), cabazitaxel (1 µM), mitoxantrone (100 nM), abiraterone (6 µM), enzalutamide (1 µM), or vehicle 
control for 48 hours. Subsequently the synthetic androgen R1881 (1 nM) was added at t=0 to induce AR nuclear translocation. 
Time-lapse images were acquired every 5 minutes at multiple locations per sample. A, Dynamics and quantification of nuclear 
AR nuclear localization. B, Representative high resolution confocal images of AR localization were acquired after 130 minutes of 
incubation with R1881. Bar represents 10 µm. C, Docetaxel and cabazitaxel cause microtubule rearrangement. High resolution 
confocal images of Hep3B cells expressing YFP-tubulin were acquired after treatment with docetaxel (1 µM), cabazitaxel (1 µM), 
mitoxantrone (100 nM), abiraterone (6 µM), enzalutamide (1 µM), and vehicle control for 48 hours. Bar represents 10 µm.
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disCussion
In this study we present in vitro evidence for cross-resistance between taxanes 
(docetaxel and cabazitaxel) and AR targeting compounds abiraterone and enzalutamide 
in mCRPC. Furthermore, our data demonstrate that docetaxel, cabazitaxel, abiraterone 
and enzalutamide all act on AR nuclear transport, which is a crucial step in AR signaling, 
and provide a mechanistical explanation for potential cross-resistance between the two 
taxanes that are currently registered for treatment in mCRPC and the novel AR targeting 
agents abiraterone and enzalutamide. The observation that mitoxantrone did not affect 
AR transport and did not show impaired efficacy in the abiraterone- and enzalutamide-
resistant cells, strengthened our hypothesis that cross-resistance between both taxanes 
and the hormonal agents might be caused by the effects on AR nuclear import of these 
compounds. 
Darshan et al. recently reported that paclitaxel inhibits AR nuclear import [20]. 
Paclitaxel however, is not approved for use in mCRPC. Zhu et al. showed that also 
docetaxel impairs AR signaling [8]. Thus far no data have been reported on cabazitaxel, 
which was approved in 2010 by the US Food and Drug Administration (FDA) and in 2011 
by the European Medicines Agency (EMA) for the use in mCRPC after prior treatment with 
docetaxel. To our knowledge, we are the first to describe preclinical evidence for cross-
resistance and the effects on AR translocation dynamics by docetaxel, cabazitaxel, and 
abiraterone, drugs that are all three approved for the treatment of mCRPC. 
Interestingly abiraterone is able to block AR nuclear import in the presence of 
R1881. Like testosterone or dihydrotestosterone, R1881 does not require steroidogenic 
conversion to bind and activate the AR. Consequently, our observed inhibition of AR 
nuclear transport cannot be related to CYP17A1 inhibition, a therefore must be an effect 
of abiraterone directly acting on the AR. This finding is supported by Richards et al, who 
found that abiraterone binds and inhibits AR at high but clinically relevant concentrations 
(≥5 µM) [21, 22]. Our observations of abiraterone and enzalutamide both directly 
inhibiting AR nuclear translocation, and cross-resistance between these compounds in 
vitro are concordant with recent clinical observations demonstrating modest efficacy of 
abiraterone in patients with mCRPC progressing after enzalutamide [24, 25], as well as 
modest efficacy of enzalutamide in patients progressing after abiraterone [26].
The inhibiting effects on AR nuclear import by abiraterone and docetaxel strongly 
suggest a common mechanism of action in mCRPC. Such an interaction is further 
augmented by our observed cross-resistance between these compounds in vitro. Although 
the exact mechanism needs to be further elucidated, this data may explain recent clinical 
observations of cross-resistance between abiraterone and docetaxel in mCRPC reported 
by Mezynski et al [1]. 
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figure 4. Docetaxel, cabazitaxel, abiraterone and enzalutamide inhibit AR nuclear import in prostate cancer cells. PC346C cells 
stably expressing GFP-AR were pre-treated with docetaxel (1 µM), cabazitaxel (1 µM), mitoxantrone (100 nM), abiraterone (6 µM), 
enzalutamide (1 µM), or vehicle control for 4 hours. High resolution confocal images were acquired after 2 hours of incubation 
with 1 nM R1881 to induce AR nuclear translocation. 
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The effects of docetaxel and cabazitaxel on AR transport could be explained by 
a mechanism proposed by Thadani-Mulero et al. in which AR transport is facilitated by 
microtubules and the motor protein dynein [7]. This model could help to better understand 
the effect of taxanes on AR and the molecular basis of taxane resistance._ENREF_7 In our 
study the effects of the taxanes on AR transport were more pronounced in PC346C as 
compared to the Hep3B model system, suggesting that the ability of taxanes to suppress 
microtubule dynamics may be cell specific, exerting optimal effects on prostate cancer 
cells.
With new compounds for the treatment of mCRPC becoming available for clinical 
use, it is warranted, especially in light of our current findings, to determine the optimal 
treatment sequence of these compounds in the management of patients with mCRPC. 
Following the recent approval by FDA and EMA of abiraterone for the use prior to docetaxel 
chemotherapy, prospective clinical research aiming to define the treatment sequence 
that provides the maximum survival benefit has become of paramount importance. The 
ultimate proof of clinical cross-resistance between these compounds and the magnitude 
of the impact of drug sequencing can only be answered in a prospective clinical trial of 
abiraterone or enzalutamide followed by taxane chemotherapy, versus chemotherapy 
followed by abiraterone or enzalutamide. 
In conclusion we found substantial evidence for cross-resistance between the taxanes 
docetaxel and cabazitaxel, and the new hormonal agents abiraterone and enzalutamide 
in vitro. These preclinical observations are concordant with clinical reports of cross-
resistance between docetaxel and abiraterone, as well as abiraterone and enzalutamide in 
mCRPC [1, 24-26]. Since docetaxel, cabazitaxel, abiraterone and enzalutamide all interfere 
with AR signaling, this strongly suggests a common mechanism of action, and thus a 
potential mechanism for cross-resistance in mCRPC. Prospective clinical studies should 
further define if this cross-resistance impacts the treatment sequence of these treatment 
options in patients with mCRPC. Survival benefit of abiraterone has been shown post-
docetaxel, but since the efficacy of the taxanes may be impaired in this setting, it is 
critically important to demonstrate overall survival benefit when testing these agents 
prior to chemotherapy.
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suppleMenTary figures
supplementary figure s1. Protein expression of AR, PSA and GAPDH control for PC346C, PC346Abi101 and PC346Enza. Total 
proteins were extracted from PC346C, PC346Abi101 and PC346Enza cells and AR, PSA and GAPDH (loading control) were 
assessed by western blot.
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supplementary figure s2. Docetaxel (1 µM), cabazitaxel (1 µM), mitoxantrone (100 nM), abiraterone (6 µM), and enzalutamide 
(1 µM), used in similar concentrations as for AR nuclear translocation studies, did not inhibit cell viability of Hep3B GFP-AR cells 
after 48 hours of treatment (A and C), showing improved overall cell viability compared to day 0 (B and D). Cell viability was 
assessed using MTT-assay with 48 hours of incubation. Four replicates per condition were used. Data are expressed as mean cell 
viability compared to control ± SEM, and mean cell viability compared to day 0 ± SEM of 3 independent experiments. 
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TARGeTiNG THe ANdRoGeN ReCePToR CoNfeRs iN 
vivo CRoss-ResisTANCe beTweeN eNzAluTAMide 
ANd doCeTAxel, buT NoT CAbAziTAxel, iN 
CAsTRATioN-ResisTANT PRosTATe CANCeR
Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, Corrina M.A. de Ridder, Erik 
A.C. Wiemer, Ron H.J. Mathijssen, Ronald de Wit, Wytske M. van Weerden
Eur Urol 2015;67(6):981-5 
aBsTraCT 
Treatment options for metastatic castration-resistant prostate cancer (CRPC) 
have evolved with the established benefit of novel androgen receptor (AR)-targeted 
agents abiraterone and enzalutamide in the pre-chemotherapy setting. At the same 
time, concerns of cross-resistance between the taxanes (i.e. docetaxel and cabazitaxel) 
and these AR-targeted agents have risen, and the optimal drug treatment sequence is 
unknown. Here, we investigated the in vivo efficacy of docetaxel and cabazitaxel in 
enzalutamide-resistant CRPC, and mechanisms of cross-resistance between these agents. 
Castrated mice harboring enzalutamide-resistant tumors and enzalutamide-naïve 
tumors were treated with docetaxel and cabazitaxel. Tumor growth kinetics, AR nuclear 
localization, AR regulated gene expression, Ki67 expression, and serum levels of PSA, 
docetaxel, and cabazitaxel were analyzed. Docetaxel inhibited tumor growth, AR nuclear 
localization, and AR regulated gene expression in enzalutamide-naive tumors, but did 
not in enzalutamide-resistant tumors, demonstrating in vivo cross-resistance. In contrast, 
cabazitaxel remained highly effective in enzalutamide-resistant tumors and demonstrated 
superior anti-tumor activity as compared to docetaxel, independent of the AR pathway. 
These findings demonstrate that the AR pathway is able to confer in vivo cross-resistance 
between enzalutamide and docetaxel, but not cabazitaxel, in CRPC. 
patient summary: We found reduced efficacy of docetaxel, but not cabazitaxel, in 
enzalutamide-resistant prostate cancer. 
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inTroduCTion
For almost a decade docetaxel has been the standard first-line chemotherapy for 
metastatic castration-resistant prostate cancer (mCRPC). In recent years, treatment 
options for mCRPC have evolved with the introduction of cabazitaxel, abiraterone, and 
enzalutamide, that all prolonged survival in the post-docetaxel setting [1]. Recently, 
the treatment paradigm has changed with evidence that novel AR targeted therapies 
abiraterone and enzalutamide are effective when administered to men with mCRPC also 
before chemotherapy [2, 3]. With these novel AR targeting therapies also available in the 
pre-chemotherapy setting, treatment sequencing has become increasingly challenging, 
especially since concerns have been raised regarding the efficacy of docetaxel when 
used after abiraterone [4, 5]. Clinical cross-resistance has been suggested in retrospective 
studies that demonstrated reduced efficacy of docetaxel in men with mCRPC who had 
previously been treated with abiraterone [4, 5]. Moreover, a preclinical study by our group 
identified inhibition of  AR nuclear translocation as an overlapping working mechanism 
that potentially confers cross-resistance between taxanes and AR targeted agents 
abiraterone and enzalutamide [6]. Interestingly, retrospective clinical data suggested 
that cabazitaxel, in contrast to docetaxel, remains effective in men with mCRPC after prior 
abiraterone [7, 8]. The efficacy of docetaxel and cabazitaxel after first-line enzalutamide is 
yet unknown.
With the availability of novel hormonal agents before chemotherapy, there is an 
urgent need to investigate the optimal treatment sequence, and potential mechanisms 
of cross-resistance between the current treatment options. Here, we investigated the in 
vivo efficacy of docetaxel and cabazitaxel in castration-resistant prostate cancer (CRPC) 
with acquired resistance to enzalutamide, and mechanisms of cross-resistance between 
these agents.
MaTerials and MeThods
Cell lines and xenografts
The PC346C patient-derived prostate cancer xenograft and cell line were developed 
and maintained as described previously [9, 10]. The enzalutamide-resistant PC346Enza 
cell line was generated from the parental PC346C by long time culturing in the presence 
of enzalutamide(1 uM) [6]. Both PC346C and PC346Enza cells harbor wildtype AR.
in vivo experiments
PC346Enza and parental PC346C cells were subcutaneously inoculated in 
immunodeficient male (NMRI) mice. Mice were castrated when tumors reached a volume 
between 150 and 200 mm3. After castration, mice were randomized to treatment with a 
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single intraperitoneal dose of docetaxel (33 mg/kg), cabazitaxel (33 mg/kg), or placebo 
when a tumor volume of 300 mm3 was reached. Mice bearing the enzalutamide-resistant 
PC346Enza xenografts were kept under selection pressure with enzalutamide until they 
received their assigned treatment. To confirm enzalutamide resistance, castrate mice 
bearing PC346C and PC346Enza tumors were randomized to receive placebo or oral 
enzalutamide once daily (Axon Medchem, Groningen, the Netherlands) at a dose of 60 mg/
kg, which is in line with the optimal biological dose in mice of 30-100 mg/kg as reported 
by Clegg et al [11]. All placebo treated PC346C xenografts were pooled for analyses. Tumor 
volumes were measured twice a week, and blood samples were taken every 2 weeks and 
analyzed for serum PSA levels. Tumor volumes were analyzed after a follow-up of 77 days 
after the start of treatment. Mice were euthanized before day 77 if a tumor volume of 
>1500-2000 mm3 was reached. Available serum PSA samples taken at baseline (at least 2 
weeks after castration), were compared with PSA levels after approximately 77 days or end 
of treatment (whichever came first). All animal experiments were approved by the Animal 
Experiments Committee under the Dutch Experiments on Animals Act. Experiments were 
analyzed using Graphpad 5.0. An unpaired t-test was used for statistical evaluation.
pharmacokinetics
To determine whether enzalutamide affected the pharmacokinetics of docetaxel 
and cabazitaxel, a separate experiment was conducted in mice that were pretreated with 
enzalutamide (60 mg/kg) for at least 2 weeks and subsequently received an intraperitoneal 
injection of docetaxel or cabazitaxel (both 33 mg/kg). Non enzalutamide-pretreated mice 
also received an injection with docetaxel or cabazitaxel. Three hours after administration, 
blood samples were taken to determine the plasma concentration of both taxanes using 
a validated LC/MS/MS based assay as described previously [12, 13]. 
rna isolation and real-time pCr (rT-pCr)
Total RNA from the xenografts was isolated using RNA-Bee (Tel-Test, Inc, Friendwood, 
TX). RT-PCR was performed using a 7500 Fast Real-Time PCR System (Applied Biosystems, 
Thermo Fisher Scientific Inc., Waltham, MA), as described previously [14]. Gene expression 
was normalized against the average of two housekeeping genes (GAPDH and PBGD) 
using the delta Ct method. RT-PCR experiments were carried out in duplo. 
immunohistochemistry
Immunohistochemistry to determine AR nuclear localization and Ki67 expression of 
the xenografts was performed using formalin-fixed paraffin embedded tissue sections. 
AR nuclear localization was determined after incubation with anti-AR (SP107, Dako), 
treatment with anti-rabbit (Ultramap) and visualization with DAB/H2O2. Ki67 was used 
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as a biotinylated anti mouse complex, detected with streptavidine-HRP, and visualized 
using DAB/H202.  AR nuclear localization scores were composed of the sum of the nuclear 
AR score (0 for no stain, 1 for weak stain, and 2 for intense stain), each multiplied by 
the corresponding percentage of cells [15]. Ki67 score was calculated  by estimating 
the percentage of positive cells in the whole tumor section. Tissue sections that were 
not evaluable due to necrosis or insufficient cancer cells were excluded from analysis. 
Immunohistochemistry slides were scored by two readers (RJvS and CFK), blinded for 
treatment group and tumortype. The final blinded scored was made by consensus.
resulTs
We first confirmed that the PC346Enza xenograft was resistant to enzalutamide in 
vivo (Fig.1A-B). Docetaxel showed good tumor responses as compared with placebo 
in castrate male mice bearing enzalutamide-naïve PC346C tumors (-78% mean tumor 
volume change from baseline (TVC), SEM +/- 7%), whereas its efficacy was impaired in 
mice bearing enzalutamide-resistant PC346Enza tumors (+364%TVC, SEM +/- 69%) 
demonstrating cross-resistance between docetaxel and enzalutamide in vivo (P<0.01) 
(Fig.1C-D). Progression-free survival and tumor growth curves over time are shown in 
Fig.1E-F, and Supplementary figure 1. Concordant with the observed tumor responses, 
docetaxel reduced serum PSA levels as compared to placebo in castrate mice bearing 
PC346C, while it did not in mice bearing PC346Enza tumors (Fig. 2A-B). Thus cross-
resistance between docetaxel and enzalutamide was not only observed at the level of 
tumor growth, but also in terms of clinically relevant serum PSA response, which is directly 
related to tumor volume. 
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figure 1. (a and B) Castrate male mice harboring enzalutamide-resistant PC346Enza tumors and the parental enzalutamide-
naïve PC346C tumors were treated with daily oral enzalutamide (60 mg/kg) and placebo. (C and d) Castrate mice bearing 
PC346Enza and PC346C tumors were treated with docetaxel (33 mg/kg) and cabazitaxel (33 mg/kg) using a single intraperitoneal 
injection, or placebo. The percentage of tumor volume change form baseline was calculated after a cut-off of 77 days. Differences 
between groups were evaluated using an unpaired t-test. (*) represents p<0.05, (**) represents p<0.01. The exact p-values are 
quoted for comparisons with borderline significance (0.05<p<0.10), and the absence of a star indicates p>0.10. Bars represent 
individual mice. (e and f) Progression-free survival during 77 days was plotted with progression defined as a ≥50% increase in 
tumor volume. 
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     Tumor responses for cabazitaxel were similar in PC346Enza and PC346C tumors, 
demonstrating that there was no cross-resistance between enzalutamide and cabazitaxel 
(Fig.1C-D). While docetaxel efficacy was impaired in mice bearing PC346enza tumors 
(+364%TVC, SEM +/- 69%), cabazitaxel remained very effective (-70%TVC, SEM +/- 10%) 
and demonstrated greater anti-tumor activity (P<0.01) and serum PSA declines (Fig. 2A-B) 
as compared to docetaxel.
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figure 2. (a and B) Blood samples of mice harboring enzalutamide-resistant PC346Enza tumors and the parental PC346C 
tumors were taken every 2 weeks to determine serum PSA levels. Baseline serum PSA samples taken at least 2 weeks after 
castration were compared with PSA levels after approximately 77 days or end of treatment (whichever came first). The mean 
percentage of PSA change from baseline +/- SEM was plotted. Differences between groups were evaluated using an unpaired 
t-test. (*) represents p<0.05, (**) represents p<0.01. The exact p-values are quoted for comparisons with borderline significance 
(0.05<p<0.10), and the absence of a star indicates p>0.10.
Plasma concentrations of docetaxel and cabazitaxel were similar in enzalutamide 
pretreated versus non-pretreated control mice, indicating no effect of enzalutamide on 
the pharmacokinetics of both taxanes (Fig. 3, Table 1). Furthermore, plasma concentrations 
of docetaxel and cabazitaxel in mice were similar as compared to those reported in 
patients (Table 1) indicating that our observed cross-resistance occurs at clinical relevant 
concentrations.
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figure 3. (a and B) Plasma concentrations 3 hours after intraperitoneal injection of docetaxel (33mg/kg) and cabazitaxel (33mg/
kg) were measured in mice that were pre-treated with enzalutamide (60 mg/kg ) and compared to mice that were non-pretreated. 
Plasma concentrations were measured using LC/MS/MS. Scatter plots including mean and range were used to represent the 
values. Differences between groups were evaluated using an unpaired t-test. Exact p-values are quoted in supplementary table 
1. The absence of a star indicates that no statistical significant differences were observed. 
Table 1. Plasma concentrations of docetaxel and cabazitaxel in mice.
Enza-pretreated Non-pretreated P-value Patient plasma 
levels [16, 17]*
P-value as 
compared with 
mice
(t-test)
plasma docetaxel,
Mean (sd) (ng/ml)
1667 (639) 1451 (1113) 0.63 2180 (170) 0.07
plasma 
cabazitaxel,
Mean (sd) (ng/ml)
871 (634) 1306 (931) 0.30 535  (305) 0.14
*Patient plasma levels were derived from corresponding phase I studies [16, 17]
While the expression of AR was similar among treatment groups (Fig. 4A-B), docetaxel 
was able to affect the downstream AR pathway by inhibiting intratumoral AR nuclear 
localization (Fig. 5A,C) and the AR target gene PSA (Fig. 4C) in PC346C tumors. In contrast, 
while expressing lower baseline levels, docetaxel did not inhibit AR nuclear localization 
and PSA expression as compared to placebo in PC346Enza tumors (Fig. 5A,C, and 4D), 
indicating a reduced anti-tumor activity via the AR pathway in these tumors. This impaired 
anti-AR effect in PC346Enza tumors was also observed for cabazitaxel (Fig. 5A and 4C-D) 
and enzalutamide (Fig. 4G-H). Although the effects of cabazitaxel via the AR were impaired 
in enzalutamide-resistant tumors, it demonstrated stronger antiproliferative properties 
compared to docetaxel as depicted in Ki67 staining (Fig. 5B-C), independent of the AR 
pathway. 
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figure 4. (a and B). Androgen receptor (AR) expression of enzalutamide-resistant PC346Enza tumors versus enzalutamide-
naive PC346C tumors treated with docetaxel, cabazitaxel and placebo. (C and d) Expression of the downstream AR target 
gene PSA in PC346Enza versus PC346C tumors treated with docetaxel, cabazitaxel and placebo. (e and f) AR expression in 
PC346Enza versus PC346C tumors treated with enzalutamide and placebo. (f and g) Expression of the downstream AR target 
gene PSA in PC346Enza versus PC346C tumors treated with enzalutamide and placebo. RNA from the tumors was isolated and 
RT-PCR was performed as described in the supplementary methods. Gene expression was normalized against the average of 
two housekeeping genes (GAPDH and PBGD). Differences in gene expression were displayed using scatterplots including mean 
(+/- SEM) and tested using an unpaired t-test. (*) represents p<0.05, (**) represents p<0.01. The exact p-values are quoted for 
comparisons with borderline significance (0.05<p<0.10) and the absence of a star indicates p>0.10. 
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disCussion
In this study, we present the first evidence for in vivo cross-resistance between docetaxel 
and enzalutamide in CRPC. We showed that docetaxel efficiently impaired AR nuclear 
localization and consequently AR signaling in enzalutamide-naïve tumors, while it did 
not in enzalutamide-resistant tumors. These results indicate that the inhibiting effects of 
docetaxel on the AR represent part of its antitumor activity, which is impaired by previous 
AR targeted therapy such as enzalutamide. In this light, it could also explain the reduced 
efficacy of docetaxel when used after abiraterone that was observed in retrospective 
clinical studies [4, 5]. Our findings are especially of interest with the increasing use of 
enzalutamide and abiraterone pre-chemotherapy.
In contrast to docetaxel, cabazitaxel demonstrated robust tumor and PSA responses 
in enzalutamide-resistant tumors, while the effects on AR signaling were reduced as 
compared to those in enzalutamide-naïve tumors. These observations indicate that 
cabazitaxel is less dependent on its inhibitory effects on the AR pathway, and exerts 
greater anti-tumor activity via AR independent mechanisms as compared to docetaxel. 
This is concordant with clinical observations [7, 8], and is probably caused by a higher 
potency of cabazitaxel to suppress microtubule dynamics as compared to docetaxel, with 
faster drug uptake and better intracellular retention[18]. This is further augmented by our 
observed lower Ki67 expression in enzalutamide-resistant tumors treated with cabazitaxel 
as compared to docetaxel, indicating stronger antiproliferative properties. The greater 
potency of cabazitaxel after AR-targeted treatment might have clinical implications, 
as currently docetaxel is the standard first-line chemotherapy for men with mCRPC. 
Considering the superior efficacy of cabazitaxel over docetaxel in enzalutamide-resistant 
tumors, our results provide a rationale for clinical studies comparing cabazitaxel with 
docetaxel in men with mCRPC who progressed on first-line enzalutamide or abiraterone. 
In summary, we demonstrated that a reduced inhibition of the AR pathway by 
docetaxel in enzalutamide-resistant CRPC confers cross-resistance between these 
drugs in vivo. Cabazitaxel remained highly effective in enzalutamide-resistant tumors, 
demonstrating greater antiproliferative properties independent of the AR pathway. This 
merits further clinical evaluation of cross-resistance and the optimal treatment sequence 
for patients with mCRPC.
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figure 5. (a and B) AR nuclear localization and Ki-67 staining of enzalutamide-resistant PC346Enza tumors and the parental 
enzalutamide-naïve PC346C tumors. Immunostainings were scored by two readers, blinded for treatment and type of tumor. 
The score was composed using a sum of the nuclear AR score (0 for no stain, 1 for weak stain, and 2 for intense stain), each 
multiplied by the corresponding percentage of cells . Ki-67 score was calculated by estimating the percentage of positive cells 
in the whole tumor section. Differences in AR nuclear localization and Ki67 expression were tested using an unpaired t-test. (*) 
represents p<0.05, (**) represents p<0.01. The exact p-values are quoted for values with borderline significance (0.05<p<0.10), 
and the absence of a star indicates p>0.10.   
(C) Representative pictures of AR nuclear localization and Ki67 staining in PC346Enza and PC346C tumors treated with docetaxel, 
cabazitaxel and placebo. 
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suppleMenTary figures 
 
supplementary figure 1. (A and B) Individual tumor growth curves over time in castrate mice bearing PC346C and PC346Enza 
tumors. Mice were treated with docetaxel (33 mg/kg), cabazitaxel (33 mg/kg) using a single intraperitoneal injection, or placebo.
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aBsTraCT
Background: The treatment armamentarium for metastatic castration-resistant prostate 
cancer (mCRPC) has expanded with the introduction of several new therapies. In this 
treatment continuum, it is unclear whether the efficacy of cabazitaxel is affected by prior 
novel androgen receptor targeted therapies (ART) abiraterone and enzalutamide.
objective:  We aimed to investigate the influence of prior ART on the efficacy of cabazitaxel 
in men with mCRPC.
design, setting and participants: Data from an ongoing prospective, multicenter, 
randomized phase II trial (CABARESC) were used comprising 114 men with mCRPC treated 
with cabazitaxel (25 mg/m2 every 3-weeks) plus prednisone in the post-docetaxel setting.
 
outcome measurements and statistical analysis: The primary endpoints of this 
unplanned analysis were PSA response (≥50%), and overall survival (OS). Univariate and 
multivariable analyses were conducted to investigate the influence of prior ART on the 
efficacy of cabazitaxel as defined by OS and PSA response rates.
results and limitations: From the 114 patients included in this analysis, 44 men received 
prior ART and 70 men did not receive prior ART before treatment with cabazitaxel. PSA 
response rates (≥50%) while on cabazitaxel treatment were similar in patients with and 
without prior ART (34% versus 40%, respectively, P=0.53). Likewise, median OS was not 
significantly different between men with and without prior ART (9.8 months versus 
10.6 months, respectively, logrank P=0.65). In multivariable analysis, the only variables 
significantly associated with OS were performance score, alkaline phosphatase and 
albumin at baseline. This study is limited by its modest sample size.
Conclusion: Our study showed that prior treatment with ART did not influence the efficacy 
of cabazitaxel in men with mCRPC. With emerging evidence of cross-resistance between 
the currently available therapies in mCRPC, cabazitaxel provides a good treatment option 
irrespective of prior treatment.
patient summary: Cabazitaxel efficacy seems not affected by prior treatment with 
abiraterone or enzalutamide.
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inTroduCTion 
The treatment armamentarium for metastatic castration-resistant prostate cancer 
(mCRPC) has changed considerably over the past few years, with the introduction of 
several new drugs that provide substantial survival benefits [1-5]. Cabazitaxel, abiraterone 
and enzalutamide all demonstrated survival benefit in the post-docetaxel setting and 
subsequently became approved for the treatment of this disease [1, 2, 5]. Moreover, the 
novel androgen receptor (AR)-targeted therapies abiraterone and enzalutamide have 
shown survival improvement when used in the pre-docetaxel setting [1, 2, 5-7]. These 
advances also come with new challenges. At the current time, no established predictive 
biomarkers for the available treatments exist, and the optimal drug treatment sequence 
is still undetermined. 
Retrospective series studies suggested that the overall survival benefits obtained by 
the new therapies cannot be simply added up, as cross-resistance between docetaxel 
and AR-targeted agents has been observed [8-10]. Reduced efficacy of docetaxel 
was observed in men with mCRPC who had previously been treated with abiraterone, 
suggesting clinical cross-resistance [8-10]. In addition, preclinical studies revealed that 
the androgen receptor (AR) is able to confer cross-resistance between enzalutamide 
and docetaxel in vivo, which is induced by an overlapping working mechanism on AR 
nuclear translocation [11, 12]. These findings raise concern whether prior treatment with 
abiraterone or enzalutamide may affect the efficacy of subsequent cabazitaxel treatment. 
Emerging preclinical and retrospective clinical data suggested that cabazitaxel, in contrast 
to docetaxel, has sustained efficacy in men with mCRPC after prior abiraterone treatment 
[13, 14]. In two retrospective studies, cabazitaxel efficacy after abiraterone treatment was 
investigated and compared to the TROPIC trial of cabazitaxel in abiraterone-naïve patients 
as an historical control group [2, 13, 14]. These studies suggested retained efficacy of 
cabazitaxel after prior abiraterone, as the observed PSA response rates were similar when 
compared to the TROPIC trial. However, to date, the efficacy of cabazitaxel has never been 
directly compared between patients with and without prior abiraterone or enzalutamide 
within the same study population, which hampers clinically meaningful conclusions. Here, 
we used data from a prospective, randomized, multicenter phase II study, to investigate 
the influence of prior AR-targeted therapies (ART) abiraterone and enzalutamide on the 
efficacy of cabazitaxel.
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paTienTs and MeThods
study population and data collection
CABARESC (Dutch Trial Registry number: NTR 2991, EudraCT number: 2011-003346-
40) is an ongoing randomized, open-label, multicenter, phase II trial that was designed 
to investigate the effects of budesonide on cabazitaxel induced diarrhea. The primary 
endpoint of the original study was the incidence of grade 2-4 diarrhea. Eligible men 
were randomized to either cabazitaxel (25 mg/m2) and prednisone (10 mg daily) plus 
oral budesonide (9 mg daily during 44 days), or standard cabazitaxel 25 mg/m2 plus 
prednisone (10 mg daily). It has been shown previously that budesonide does not affect 
the pharmacokinectics of cabazitaxel [15]. 
Full inclusion and exclusion criteria of the CABARESC trial are shown in the 
Supplementary materials and methods. In brief, patients were eligible if they had mCRPC 
with documented disease progression during or after treatment with docetaxel, as defined 
by rising PSA levels, appearance of new lesions or documented disease progression based 
on CT scan or bone scan. Cabazitaxel treatment was continued until disease progression, 
unacceptable toxicity, or until 10 cycles have been administered. Patients were randomly 
assigned to the treatment groups through a centralized stratified randomization 
process using the following stratification factors: center, age (≥65 versus <65 years) and 
previous radiotherapy (yes versus no). In this study, data were prospectively collected at 
baseline and for every cycle including: hematology and biochemistry laboratory values, 
performance status, age, prior treatment with ART, duration of treatment with ART, PSA 
values, and survival status. 
For the current unplanned analysis, we included patients from the ongoing CABARESC 
trial who were randomized before May 15 2014 and had a completed off-protocol form. 
As the CABARESC study is still recruiting, the primary endpoint of the original study 
(incidence of grade 3/4 diarrea) was not reported, and no data per arm were analyzed. The 
CABARESC study was approved by the institutional review board at each participating 
center. Written informed consent was obtained from all participants.
data collection and definitions 
The primary objective of the current analysis was to explore the influence of prior ART 
on the efficacy of cabazitaxel in men with mCRPC. Primary endpoints of this analysis were 
the proportion of patients with a ≥50% PSA response, and OS. As a secondary endpoint, we 
investigated PSA progression-free survival (PSA-PFS). For the definition of PSA response 
and PSA-PFS, Prostate Cancer Working Group 2 (PCWG2) criteria were used [16]. As 
recommended by the PCWG2, PSA response was defined as ≥50% decline from baseline, 
and PSA progression as a 25% increase (and a minimum of 2 ng/ml) from baseline or nadir. 
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In most cases this was confirmed by a second measurement; however confirmation was 
not routinely performed for all patients. OS was defined by time from randomization to 
death from any cause. Since bone scans and CT-scans were not performed according 
to regular intervals in the study protocol, we did not consider radiological PFS for our 
analyses. 
Descriptive statistics were used to compare baseline characteristics in the ART 
pretreated versus non-pretreated patients, with statistical evaluation using Fisher’s exact 
test for categorical variables and Kruskal Wallis test for continuous variables. OS and PSA-
PFS were calculated using the Kaplan-Meier method with statistical evaluation by the 
logrank test. 
Model building and statistical considerations
We conducted univariate and multivariable Cox regression analyses including prior 
treatment with ART (yes/no), and the duration of prior ART to investigate its effect on 
PSA response and OS of men treated with cabazitaxel. Cox proportional hazards models 
were constructed to adjust for known prognostic factors from the Halabi nomogram 
[17] including: baseline serum PSA, LDH, albumin, alkaline phosphatase, hemoglobin, 
and performance score. The multivariable model was constructed using backward 
elimination at the 5% level. A log transformation was applied to variables with a non-
normal distribution.
resulTs 
Baseline characteristics 
In the CABARESC trial, 141 patients who had a completed off-study form were 
randomized before May 15, 2014. Of these 141 patients, 27 men were excluded from 
analysis for the following reasons: 5 patients had missing PSA values at baseline, 9 patients 
were randomized but never received cabazitaxel treatment due to rapid worsening of 
performance status or death, and 13 patients had received previous study treatment with 
orteronel (Figure 1). Patients who received prior orteronel were excluded from this analysis 
since this is not a clinically approved regimen in the treatment of mCRPC. All patients had 
received prior docetaxel chemotherapy. Forty-four out of 114 patients (39%) had received 
prior ART in the post-docetaxel setting, of whom 41 had received abiraterone, 5 had 
received enzalutamide, and 2 had received both. The remaining 70 patients had received 
no prior ART before study treatment with cabazitaxel. 
Baseline characteristics of the men with and without prior ART are shown in table 1. 
Known prognostic variables were evenly distributed among subgroups, except for a 
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significantly lower albumin level in men with prior ART (table 1). The median number of 
cabazitaxel cycles received was 6 in the ART group, and 5 for men without prior ART.
figure 1. CONSORT diagram
The influence of prior novel ar-targeted therapy on the efficacy of cabazitaxel
PSA response rates (≥50%) while on cabazitaxel treatment were similar in patients 
with and without prior ART (34% versus 40% respectively, P=0.53). Waterfall plots of the 
maximum PSA change while on cabazitaxel treatment for men with and without prior ART 
are shown in Fig. 2. Likewise, median PSA-PFS was not significantly different between the 
two groups. Men who received prior ART had a median PSA-PFS of 4.8 months, versus 6.5 
months for men without prior ART (logrank P=0.32) (Fig. 3A). Median OS was similar for 
patients previously treated with ART versus patients who were not previously treated with 
ART, with a median OS of 9.8 versus 10.6 months respectively (logrank P=0.65) (Fig. 3B). 
univariable and multivariable analyses for os and psa response.
Factors significantly associated with OS in univariate analysis are shown in table 2 
and included performance score, alkaline phosphatase, albumin, hemoglobin and LDH at 
baseline. Prior ART and the duration of prior ART were not significantly associated with OS 
(HR=1.14; 95%CI: 0.66-1.97, P=0.65 and HR=1.00; 95%CI: 0.92-1.09, P=0.98 respectively). 
From the significant variables in univariate analysis, a multivariate model for OS was 
constructed (table 2). The only variables significantly associated with OS in multivariable 
analysis were performance score, alkaline phosphatase and albumin at baseline. Univariate 
CABARESC study
Patients randomized before May 
15, 2014 with a completed off-
study form (N=141)
N=9 never received study 
treatment
N=13 received previous 
treatment with orteronel
N=5 with missing baseline 
PSA values
N=44 received previous novel 
AR targeted therapy
N=41 abiraterone
N=5 enzalutamide
N=2  both
N=70 did not receive prior 
novel AR-targeted therapy
. .
.
.
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logistic regression analyses for PSA response (≥50%) are shown in Supplementary table 1. 
Prior ART or the duration of prior ART were not significantly associated with PSA response. 
Baseline hemoglobin was the only variable that was significantly associated with PSA 
response. 
Table 1. Baseline characteristics of men with and without prior novel AR targeted therapy.
Characteristic
prior abiraterone 
or enzalutamide
no prior abiraterone 
or enzalutamide
P-value
Number of patients 44 70
Age, years, median (range) 69 (53-83) 68 (49-82) 0.093
WHO performance score n (%)
0 18 (41) 25 (36) 0.56
1 25 (57) 44 (63)
Missing 1 1
PSA, ng/ml, median (range) 210 (15-5000) 154 (12.5-4172) 0.25
LDH at baseline, median (range) 287 (90-724) 273 (38-1843) 0.83
Hemoglobin at baseline, mmol/L, median (range) 8 (6-10) 8 (5-9) 0.96
Alkaline phosphatase at baseline, IU/L, median (range) 124 (50-907) 126 (43-1023) 0.83
Albumin at baseline, g/L, median (range) 37 (26-46) 41 (25-49) 0.013
Duration of treatment with abiraterone/enzalutamide, 
months, median (range)
6.1 (0.9-22) -
PSA - prostate-specific antigen; LDH - Lactate Dehydrogenase
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figure 2. waterfall plots of the maximum PSA change from baseline during treatment with cabazitaxel in men with (A) and 
without (B) prior novel AR-targeted therapy
disCussion
In this study, we demonstrated that there was no influence of prior ART on the efficacy 
of cabazitaxel. PSA response rates and OS were similar between patients with and without 
prior abiraterone or enzalutamide.  
We used data from a prospective randomized phase II study to directly compare the 
efficacy of cabazitaxel in men who were pretreated with ART versus men who were non-
pretreated. To date, only two retrospective studies have been published that investigated 
the response of patients treated with cabazitaxel after abiraterone, which compared their 
findings to historic controls [13, 14]. To our knowledge, we are the first to directly compare 
the efficacy of cabazitaxel between patients with and without prior ART within the same 
5
72
study population, using prospective trial data. 
Our observed PSA response rates in ART pretreated men (36%) are in line with those 
reported by Pezaro et al. and Al Nakouzi et al., which ranged from 40-45% [13, 14]. These 
findings are concordant with the TROPIC trial of cabazitaxel in ART-naïve men, and with 
the ART-naïve patients in the current analysis [2]. 
Table 2. Univariate and multivariable analyses for OS 
univariate Multivariable
variable
hazard ratio
P-value
hazard ratio
P-value
 (95% Ci)  (95% Ci)
Age ( ≥ median) 1.01 (0.97-1.05) 0.71
WHO performance score (1 vs. 0) 1.83 (1.01-3.32) 0.039 2.23 (1.06-4.69) 0.035
Hemoglobin at baseline 0.68 (0.53-0.88) 0.005 0.88 (0.63-1.24) 0.47
PSA at baseline 1.12 (0.92-1.37) 0.26
Alkaline phosphatase at baseline 1.84 (1.31-2.60) <0.001 1.65 (1.06-2.57) 0.026
LDH at baseline 1.69 (1.02-2.81) 0.049 0.74 (0.42-1.29) 0.29
Albumin at baseline 0.90 (0.86-0.95) <0.001 0.87 (0.81-0.92) <0.001
Prior novel AR-targeted therapy (yes/no) 1.14 (0.66-1.97) 0.65
Duration of prior AR-targeted therapy 1.00 (0.92-1.09) 0.98
PSA - prostate-specific antigen; LDH - Lactate Dehydrogenase; AR – Androgen receptor
Taken together, these findings strongly suggest that there is no cross-resistance 
between abiraterone or enzalutamide and cabazitaxel. These results are especially of 
interest, since an increasing number of reports have suggested an impaired efficacy of 
docetaxel after abiraterone, indicating cross-resistance with ART for this taxane [8-10]. 
These clinical findings are supported by preclinical findings from our group that showed 
an overlapping working mechanism on AR-nuclear translocation for both enzalutamide 
and docetaxel [11, 12]. In preclinical studies, this overlapping, AR-mediated, mechanism of 
action was able to confer cross-resistance between these drugs in vivo. Interestingly, in this 
preclinical model, cross-resistance was not observed for cabazitaxel, that demonstrated 
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sustained antitumor activity even in tumors previously treated with enzalutamide [11]. 
In the current analysis we clinically confirmed the findings from the reported preclinical 
studies, showing similar activity of cabazitaxel when delivered either before or after ART. 
An explanation for the lack of cross-resistance for cabazitaxel could be that cabazitaxel, 
in contrast to docetaxel, is less dependent on the AR for exerting its anti-tumor activity 
[11]. Moreover, it has been shown that cabazitaxel supresses microtubule dynamics more 
potently as compared with docetaxel, with higher intratumoral concentrations [18].
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figure 3. Kaplan-Meier estimates of PSA-PFS (A) and OS (B) in men treated with cabazitaxel with and without prior novel AR-
targeted therapy
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The main strength of our study is the use of prospective trial data to directly compare 
the efficacy of cabazitaxel in patients who did and did not receive prior ART within the 
same study population. Since all patients were prospectively enrolled using the same 
inclusion and exclusion criteria, this is a unique study enabling a direct comparison of 
the influence of prior ART on the efficacy of cabazitaxel. A limitation of the study is the 
modest sample size of 114 patients. Also, as an inherent limitation, the original CABARESC 
study was not designed for the aim of the current unplanned analysis and therefore had 
a different primary endpoint.
ConClusions
In conclusion, our study showed that prior treatment with ART did not influence the 
efficacy of cabazitaxel in men with mCRPC. With emerging evidence of cross-resistance 
between the currently available therapies in mCRPC, cabazitaxel provides a good 
treatment option both before and after novel AR-targeted therapies in the post-docetaxel 
setting.
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suppleMenTary TaBles
supplementary table 1. Univariate logistic regression analysis for PSA response (≥50%) 
univariate
variable
odds ratio
P-value
 (95% Ci)
Age 1.03 (0.98-1.09) 0.26
WHO performance score (1 vs. 0) 0.58 (0.26-1.25) 0.17
Hemoglobin at baseline 1.63 (1.06-2.50) 0.026
PSA at baseline 1.17 (0.88-1.56) 0.29
Alkaline phosphatase at baseline 0.64 (0.37-1.09) 0.11
LDH at baseline 0.68 (0.34-1.35) 0.27
Albumin at baseline 1.06 (0.99-1.14) 0.074
Prior novel AR-targeted therapy (yes/no) 0.78 (0.35-1.70) 0.53
Duration of prior AR-targeted therapy 1.00 (0.88-1.13) 0.98
PSA - prostate-specific antigen; LDH – Lactate Dehydrogenase; AR – Androgen receptor
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suppleMenTary MaTerials and MeThods
inclusion criteria
Metastatic castrate resistant prostate cancer (mCRPC) patients with documented disease 
progression, defined as:
 documented rising PSA levels (at least 2 consecutive rises in PSA over a reference value 
taken at least 1 week apart, or a PSA rise of ≥ 2.0 µg/l), appearance of new lesions or 
documented disease progression based on CT scan or bone scan.
Previous treatment with a docetaxel-containing regimen
Age ≤ 18 years;
WHO performance status ≤ 1 
Adequate renal function (within 21 days before randomization) defined as serum creatinin 
≤ 1.5 x ULN and/or calculated creatinin clearance ≥ 50ml/min, according to MDRD formula.
Adequate hepatic functions (within 21 days before randomization) defined as: total 
bilirubin ≤ 1.0 x ULN; alanine aminotransferase (ALAT) and aspartate aminotransferase 
(ASAT) ≤2.5x ULN, in case of liver metastasis < 5 ULN; alkaline phosphatase (AF) < 5x ULN) 
In case of bone metastasis, AF < 10x ULN is accepted;
Adequate hematological blood counts (within 21 days before randomization) defined as 
(absolute neutrophil count (ANC) ≥1.5 x 109/L and platelets ≥ 100 x 109/L);  
Castration, either surgically or by continued LHRH agonist therapy 
Written informed consent according to ICH-GCP
exclusion criteria
Impossibility or unwillingness to take oral drugs;
Serious illness or medical unstable condition requiring treatment, brain metastases 
or history of psychiatric disorder that would prohibit the understanding and giving of 
informed consent;
Use of medications or dietary supplements known to induce or inhibit CYP3A 
Known hypersensitivity to corticosteroids 
Any active systemic or local bacterial, viral, fungal - or yeast infection. 
Ulcerative colitis, Crohn’s disease or celiac disease (active or in medical history)
Ostomy
Planned/active simultaneous yellow fever vaccine
Geographical, psychological or other non-medical conditions interfering with follow-up 
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THe iNiTiAl bioPsy GleAsoN sCoRe As A 
PRediCTive MARkeR foR suRvivAl beNefiT iN 
PATieNTs wiTH CAsTRATioN-ResisTANT PRosTATe 
CANCeR TReATed wiTH doCeTAxel: dATA fRoM THe 
TAx327 sTudy
Robert J. van Soest, Ellen S. de Morrée, Liji Shen, Ian F. Tannock, Mario A. Eisenberger, and 
Ronald de Wit
Eur Urol 2014;66(2):330-6
CHAPTeR 6
aBsTraCT
Background: Since 2004 docetaxel has been the standard first-line systemic therapy for 
patients with metastatic castration-resistant prostate cancer (mCRPC). With abiraterone 
recently becoming available in the pre-docetaxel setting, it is warranted to identify 
subgroups of patients who may obtain the greatest benefit from docetaxel and particularly 
qualify for receiving docetaxel as first-line treatment for mCRPC.
objective: We aimed to identify factors that could characterize subgroups of patients 
who obtain the greatest benefit from the use of docetaxel.
design, setting and participants: TAX327 was multinational randomized phase 3 study 
that was conducted from 2000 to 2002 in 1006 men with mCRPC.
intervention: Patients were randomized to receive 3-weekly docetaxel (D3), weekly 
docetaxel (D1) or 3-weekly mitoxantrone (M), each with prednisone. 
outcome measurements and statistical analysis: We investigated whether patients 
with poorly differentiated tumors (Gleason ≥7) at diagnosis had greater benefit from D3 
as compared to M, than patients with better differentiated tumors (Gleason ≤6). Using a 
Cox model, we compared overall survival (OS), between the treatment groups within each 
subgroup of Gleason score. 
results and limitations: The TAX 327 data showed that the OS benefit of D3 versus M is 
greater in patients with high grade tumors (median OS 18.9 vs 14.5 months, p=0.009) than 
in patients with low grade tumors (median OS 21.6 vs 20.7 months, p=0.674). Limitations 
of a retrospective analysis apply.
Conclusions: The survival benefit obtained with docetaxel is most pronounced in patients 
with high Gleason score tumors (Gleason ≥7). In a time of shifting paradigms in mCRPC 
with abiraterone becoming available prior to docetaxel chemotherapy, Gleason score 
may help in selecting patients who obtain the greatest benefit from docetaxel as first-line 
treatment for mCRPC. Prospective validation of these findings is warranted.
6
82
inTroduCTion
Treatment options for patients with metastatic castration-resistant prostate cancer 
(mCRPC) have expanded in recent years with the introduction of new agents like cabazitaxel, 
abiraterone, and enzalutamide. The current standard first line chemotherapeutic agent 
docetaxel has shown survival benefit as well as palliative benefit in the TAX327 and the 
Southwest Oncology Group 99-16 studies [1, 2]. TAX327 was conducted in 1006 men 
with metastatic castration-resistant prostate cancer who were randomized to receive 
3-weekly docetaxel (D3), weekly docetaxel (D1) or 3-weekly mitoxantrone (M), each with 
prednisone. Overall survival (OS) of patients who were treated with D3 was superior as 
compared to M with an OS benefit of 2.9 months in the final analysis [3]. The D3 arm also 
showed better palliation, with more patients having a pain and quality of life response 
as compared to the M arm. Neutropenia was the most commonly observed grade 3 or 4 
adverse event and occurred more frequently in patients receiving D3 (32%).
Recently the COU-AA-302 trial demonstrated superior radiological progression-free 
survival and a trend towards improved OS for abiraterone in docetaxel-naïve mCRPC 
patients, as compared with prednisone alone [4]. Based on this trial, the US Federal 
Food and Drug Administration (FDA) and the European Medicines Agency (EMA) lent 
approval to the use of abiraterone in patients with metastatic mCRPC prior to docetaxel 
chemotherapy.  With new therapies available in the pre-docetaxel setting it is warranted 
to identify subgroups of patients who may respond better to one of the treatment options 
in order to better tailor therapy. 
Gleason score is one of the strongest predictors of prostate cancer mortality in men 
with localized disease [5, 6].  Men with poorly differentiated localized tumors (Gleason 
7-10) have a high probability of dying from prostate cancer within 10-years of diagnosis 
when treated conservatively [5]. High biopsy Gleason scores are observed in 9% of patients 
diagnosed with localized prostate cancer [7]. In patients progressing to mCRPC this 
proportion is higher, ranging from 25 to 30% of chemotherapy-naive patients, to around 
52% in men progressing after docetaxel chemotherapy [1, 8, 9]. Recently, a high Gleason 
score (8-10) at the time of diagnosis was reported to be an independent risk factor for 
poor response to abiraterone [10, 11]. For patients treated with the second-line taxane 
cabazitaxel poorly differentiated tumors have been associated with pronounced benefits 
in terms of progression-free survival (PFS) and OS [12, 13].  In this post-hoc analysis of the 
TAX327 study we aimed to investigate whether Gleason score at initial diagnose could 
characterize a subgroup of patients who obtain the greatest benefit from D3 treatment 
as compared to M.
6
83
paTienTs and MeThods
subjects and treatment
TAX327 was a randomized, non-blinded, phase III study, involving 1006 men with 
mCRPC, and was conducted in 24 countries. Full details of the trial are provided in the 
original report [1]. Briefly, patients were eligible if they had metastatic adenocarcinoma 
of the prostate, castrate levels of serum testosterone (<50 nl/ml), and disease progression 
during hormonal therapy defined as clinically or radiographically measurable disease or 
by PSA (prostate-specific antigen) criteria. No prior treatment with chemotherapeutic 
agents other than estramustine was allowed. Participants were randomized to receive 
3-weekly docetaxel (75 mg/m²), weekly docetaxel (30 mg/m²) or 3-weekly mitoxantrone 
(12.5 mg/m²), each with prednisone 5 mg twice daily. Baseline data were obtained for 
D3 and M in subgroups of Gleason score ≥7 and Gleason score ≤6 at diagnosis. Baseline 
information collected on each individual included PSA, age, performance status, pain 
score, hemoglobin (Hb), alkaline phosphatase, prior treatments, time from first hormonal 
treatment to start of study drug, time from diagnosis to start of study drug, the presence 
of visceral disease, and the proportion of patients with bone metastases. Treatment was 
planned for 30 weeks in the absence of progression. The primary end point of the study 
was OS. The study was conducted from March 2000 through June 2002 and was approved 
by an institutional review board at every participating institution. Written informed 
consent was obtained from all participants.
psa response
Serum PSA was measured at baseline and every three weeks during treatment. PSA 
decline was defined as a reduction of at least 30 percent or 50 percent from baseline that 
was maintained for at least three weeks.
statistical analyses
The TAX327 database was used to investigate if patients with poorly differentiated 
tumors (Gleason ≥7) at diagnosis had greater benefit from D3 as compared to M, compared 
to patients with better differentiated tumors (Gleason ≤6). To test whether there were 
differences in baseline variables known to predict OS between D3 and M in the Gleason 
score subgroups, we used Pearson Chi-square test for all categorical variables, and a two 
sample t-test with Cochran and Cox approximation for all continued variables. OS for D3 
and M in the Gleason subgroups was assessed using the Kaplan-Meier method and tested 
by a logrank test. To correct for baseline variables, OS between the treatment groups was 
further tested by a Cox regression analysis stratified by each single prognostic factor. A 
Cox regression without stratification was also performed. 
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PSA response was evaluated for D3 and M in the subgroups of Gleason score ≥7 and 
Gleason score ≤6. Fisher’s exact test was used to compare PSA response for D3 and M 
within the Gleason score subgroups.
resulTs
Baseline characteristics
Biopsy Gleason scores were available from 482 of 672 patients who received either D3 
or M. We identified 349 patients with a biopsy Gleason score of ≥7, of which 185 were in 
the D3 arm, and 164 in the M arm. There were 133 patients with a biopsy Gleason score of 
≤6, of which 62 in the D3 arm, and 71 in the M arm. Baseline characteristics of the Gleason 
score subgroups are listed in Table 1 and were well balanced between patient groups, 
except for an imbalance in the group of patients with an impaired Karnofsky performance 
score (PS) (14.6% for D3 vs 7.6% for M, p=0.034), and the proportion of patients with bone 
metastases (89.7% for D3 vs. 96.3 % for M, p=0.021).
overall survival in the gleason score subgroups
The analysis showed that the OS benefit of D3 versus M is greater in patients diagnosed 
with a biopsy Gleason score ≥7 (logrank test p=0.009, median OS 18.9 vs 14.5 months), 
compared to patients diagnosed with a biopsy Gleason score ≤6 (logrank test p=0.674, 
median OS 21.6 vs 20.7 months).  Survival curves are shown in Figure 1 and details are 
listed in Table 2. Hazard ratios (HR) for the comparison between treatment groups were 
0.69 (CI 0.52-0.91) for D3 versus M in the Gleason ≥7 subgroup and 0.90 (CI 0.56 – 1.46) for 
D3 versus M in the Gleason ≤6 subgroup. 
To correct for baseline variables, we performed a stratified Cox regression analysis on 
treatment effect as assessed by OS for the Gleason subgroups, with each single stratified 
prognostic factor. When stratified for every baseline variable known to predict OS, p-values 
for treatment effect on OS in the Gleason score ≥7 subgroup remained significant (Table 3). 
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Table 1. Baseline characteristics for D3 and M in the Gleason score subgroups.
gleason 7-10 gleason 2-6
d3 M d3 M
Number of patients 185 164 62 71
Age, years, median (range) 67 (42-92) 68 (43-83) 67 (49-86) 69 (45-86)
p-value 0.825 0.667
Visceral disease, n (%) 41 (22.2) 39 (23.8) 12 (19.4) 13 (18.3)
p-value 0.720 0.878
Karnofsky performance score ≤70 n (%) 14 (7.6) 24 (14.6) 10 (16.1) 10 (14.1)
p-value 0.034 0.742
PSA, ng/ml, median (range) 92 (0-40740) 144 (3-8022) 87 (4-2259) 113 (0-5720)
p-value 0.444 0.163
Time from first hormonal treatment to 
start study drug, years, n (%)
<2.5 years 77 (41.6) 71 (43.3) 22 (35.5) 20 (28.2)
≥2.5 years 68 (36.7) 60 (36.6) 29 (46.7) 39 (54.9)
missing 40 (21.6) 33 (20.1) 11 (17.7) 12 (16.9)
p-value 0.920 0.806
Pain at baseline n (%) 85 (45.9) 81 (49.4) 28 (45.2) 35 (49.3)
p-value 0.451 0.697
Hb at baseline, g/dl, median (range) 12.7 (8.9-16.2) 12.7 (8.6-16) 13 (6.4-16.2) 12.6 (9-15.7)
p-value 0.905 0.292
Alkaline phosphatase at baseline, IU/L, 
median (range) 191 (26-4438) 207 (51-6075) 176 (59-9900) 172 (18-5005)
p-value 0.826 0.721
Prior prostatectomy, n (%) 32 (17.3) 27 (16.5) 19 (30.6) 21 (29.6)
p-value 0.836 0.893
Prior radiotherapy, n (%) 100 (54.1) 87 (53.0) 39 (62.9) 42 (59.2)
p-value 0.851 0.659
Bone metastases, n(%) 166 (89.7) 158 (96.3) 56 (90.3) 63 (88.7)
p-value 0.017 0.766
Time from diagnosis to start study drug, 
median (range) 39.0 (2.8-197.5) 36.6 (2.3-163.6) 60.3 (8.6-234.6) 62.8 (6.6-146.3)
p-value 0.716 0.394
D3 = Docetaxel 3-weekly; M = Mitoxantrone 3-weekly; PSA = Prostate-specific antigen; Hb = Hemoglobin
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psa declines in the gleason score subgroups
Clinical benefit of D3 versus M as assessed by the proportion of patients with a ≥ 30% 
PSA decline was higher in patients with Gleason score ≥7 (71.3% for D3 vs 51.3% for M, 
p<0.001), as compared to patients with Gleason score ≤6 (67.7% for D3 vs 56.3% for M 
P=0.212) (Table 4).  Likewise, the effects of D3 versus M as assessed by the proportion of 
patients with a ≥ 50% PSA decline was also higher in the subgroup with Gleason score ≥7 
(61.9% for D3 vs 41.9% for M, p<0.001), as compared to the subgroup with Gleason score 
≤6 (58.1% for D3 vs 47.9% for M, p=0.297).
Table 2. Median overall survival for D3 and M in the Gleason score subgroups.
gleason 7-10 gleason 2-6
d3 M d3 M
Number of patients 185 164 62 71
Median OS, months 18.9 14.5 21.6 20.7
(95% CI) (16.7 - 21.2) (12.6 -16.5) (16.8 – 23.7) (17.1 – 23.5)
P-value (logrank test) 0.009 0.674
D3 = Docetaxel 3-weekly; M = Mitoxantrone 3-weekly; OS = Overall survival; CI = Confidence interval
disCussion
In this post-hoc analysis of the TAX327 study, we found that the survival benefit 
obtained with docetaxel as compared to mitoxantrone is greatest in patients with high 
Gleason score tumors (Gleason 7-10) at diagnosis. In addition, the PSA response rates for 
patients treated with docetaxel, as compared to mitoxantrone were higher in patients 
with high Gleason score tumors. 
To our knowledge, we are the first to demonstrate the pronounced benefit of docetaxel 
in high Gleason score tumors. Our results are mirrored by findings from the TROPIC-
trial, which was conducted in patients with mCRPC who progressed after docetaxel 
chemotherapy and were randomized to cabazitaxel plus prednisone (CP) or mitoxantrone 
plus prednisone (MP) [14]. In that study the OS benefit was 2.4 months superior for CP as 
compared to MP. In a recent post-hoc analysis a significant OS benefit for cabazitaxel versus 
mitoxantrone was also linked to patients with poorly differentiated tumors evaluated by 
WHO grade (median OS 15.2 months vs 12.7 months, p<0.0001), whereas for patients with 
well or moderately differentiated tumors this benefit was less robust, with a median OS of 
15.5 months for cabazitaxel and 13.3 months for mitoxantrone (p=0.56) [12]. 
In the present study, more pronounced effects of docetaxel in patients diagnosed with 
high Gleason score tumors were demonstrated by both OS benefit and PSA response rate. 
Interestingly this reflects findings of an earlier report on the TAX327 trail by Armstrong 
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et al., which demonstrated a PSA-decline of ≥ 30% within 3 months of chemotherapy 
initiation to have the highest degree of surrogacy for OS [15]. 
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figure 1. Kaplan-Meier estimates of overall survival for the D3 and the M arm in the subgroups of Gleason score 7-10 (A) and 
Gleason score 2-6 (B).
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Table 3. Stratified Cox regression analysis on treatment effect assessed by OS with each 
single stratified prognostic factor.
os d3 vs M
gleason 7-10
os d3 vs M
gleason 2-6
stratified baseline prognostic factors P-value
hazard ratio
 (95% Ci)
P-value
hazard ratio 
(95% Ci)
Without stratification 0.009
0.69
(0.52-0.91)
0.675
0.9
(0.56-1.46)
Age 0.008
0.68
(0.51-0.91)
0.654
0.9
(0.55-1.45)
Visceral disease 0.008
0.68
(0.52-0.91)
0.508
0.85
(0.52-1.38)
Bone metastases 0.020
0.72
(0.54-0.95)
0.693
0.91
(0.56-1.47)
Karnofsky performance score 0.014
0.7
(0.52-0.93)
0.625
0.89
(0.55-1.44)
PSA 0.002
0.64
(0.48-0.85)
0.776
0.93
(0.57-1.51)
Time from first hormonal treatment to start study 
drug
0.006
0.64
(0.47-0.88)
0.983
0.99
(0.57-1.74)
Pain 0.015
0.7
(0.53-0.93)
0.966
1.01
(0.62-1.64)
Hb 0.009
0.69
(0.52-0.91)
0.625
0.89
(0.55-1.44)
Alkaline phosphatase 0.002
0.63
(0.48-0.85)
0.667
0.9
(0.56-1.45)
D3 = Docetaxel 3-weekly; M = Mitoxantrone 3-weekly; CI = Confidence interval; PSA = Prostate-specific anti-
gen; Hb = Hemoglobin
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The observations that taxanes have high antitumor activity in patients with high 
Gleason score tumors are especially of interest in the light of potential contrasting findings 
with the new generation hormonal agent abiraterone. In contrast with the findings for 
docetaxel and cabazitaxel, high Gleason score (8-10) at the time of diagnosis seems to be 
an independent risk factor for poor response to abiraterone (OR 0.60, 95%CI 0.39-0.85) [10, 
11]. This finding points towards a modest efficacy of abiraterone in poorly differentiated 
tumors. With new compounds for the treatment of mCRPC becoming available for 
clinical use, and the recent FDA and EMA approval of abiraterone in the pre-docetaxel 
setting, treatment selection for individual patients becomes increasingly challenging. The 
observation in our study that docetaxel has the most pronounced anti-tumor activity in 
patients with high Gleason score tumors may provide additional guidance in treatment 
decisions regarding the use of docetaxel chemotherapy as first line treatment for patients 
with mCRPC, especially for those patients with high Gleason score tumors.
Table 4. PSA response for D3 and M in the Gleason score subgroups
gleason 7-10 gleason 2-6
d3 M d3 M
Number of patients 185 164 62 71
Data missing (n) 4 4 0 0
≥ 30% PSA decline, n(%) 129 (71.3) 82 (51.3) 42 (67.7) 40 (56.3)
p-value <0.001 0.212
≥ 50% PSA decline, n(%) 112 (61.9) 67 (41.9) 36 (58.1) 34 (47.9)
p-value <0.001 0.297
D3 = Docetaxel 3-weekly; M = Mitoxantrone 3-weekly; PSA = Prostate-specific antigen
A limitation of the current study is that the revision of the Gleason grading at the 2005 
International Society of Urological Pathology (ISUP) consensus conference led to a grade 
migration or upgrading, both in needle biopsies and radical prostatectomy specimens [16, 
17]. Billis et al. reported a change from Gleason 5–6 to group 7 and Gleason 5–6 to 8–10 
in 15.7 and 0.6% of biopsies respectively using the revised Gleason grading compared to 
the Gleason grading before 2005 [18]. These data indicate that our results might not be 
applicable to a small proportion of patients (16.3%) with Gleason score 7-10 nowadays, 
who might have had a Gleason score 2-6 the TAX327 era. However although based on 
the Gleason grading before 2005, we demonstrate a very strong relation between clinical 
benefit obtained by docetaxel and tumor differentiation in a pivotal phase III trial that led 
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to the approval of this drug, which is the largest database available to address the current 
clinical question. Taking into account the retrospective nature of the analysis, our findings 
should be prospectively validated in the current setting to evaluate the implications for 
individual treatment decisions. With prospective studies to personalize treatment choices 
for the current treatment options in mCRPC still lacking, our findings are important to take 
into account when qualifying patients for treatment with docetaxel.
Greater benefit from docetaxel in patients with high-grade tumors might be caused 
by a higher proliferation rate of these tumors. Multiple reports have found a positive 
correlation between Gleason score and the proliferation marker Ki-67 [19-21]. In breast 
cancer, clinical benefit from docetaxel-based chemotherapy has been consistently higher 
in tumors with high Ki-67 expression [22-24]. Moreover, poor histological grade in locally 
advanced breast cancer proved to be predictive of pathological complete response to 
chemotherapy containing docetaxel in a neoadjuvant setting [25]. The relationship 
between markers such as Ki-i67 and clinical benefit from docetaxel in prostate cancer still 
needs to be elucidated. 
ConClusions
In conclusion, in the setting of mCRPC, the survival benefit obtained with docetaxel 
as compared to mitoxantrone is most pronounced in patients with poorly differentiated 
tumors (Gleason 7-10). In an era of shifting paradigms in mCRPC with abiraterone 
becoming available also prior to docetaxel chemotherapy, Gleason score may serve to 
discriminate between patients who benefit most from docetaxel chemotherapy as first-
line treatment, which seems to exert efficacy particularly in high Gleason score tumors,   
or patients with better differentiated tumors in whom treatment with abiraterone might 
be more beneficial. Prospective validation of the implications for the choice of first-line 
treatment in mCRPC is warranted.
aCknowledgeMenTs
We thank the many patients who participated in the TAX327 study and the investigators 
who recruited them.
6
91
referenCes
1. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for 
advanced prostate cancer. N Engl J Med. 2004;351:1502-12.
2. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and 
prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-20.
3. Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for 
advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26:242-5.
4. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous 
chemotherapy. N Engl J Med. 2013;368:138-48.
5. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically 
localized prostate cancer. JAMA. 2005;293:2095-101.
6. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following 
radical prostatectomy. JAMA. 1999;281:1591-7.
7. Bechis SK, Carroll PR, Cooperberg MR. Impact of age at diagnosis on prostate cancer treatment and survival. 
J Clin Oncol. 2011;29:235-41.
8. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant 
prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-
controlled phase 3 study. Lancet Oncol. 2012;13:983-92.
9. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate 
cancer. N Engl J Med. 2010;363:411-22.
10. 1Azria D, Massard C, Tosi D, et al. An ambispective observational study in the safety and efficacy of 
abiraterone acetate in the French temporary authorizations for use (ATU): Predictive parameters of 
response. J Clin Oncol 2012;30 (suppl 5; abstr 149).
11. Heidenreich A, Pfister D. Treatment decisions for metastatic castration-resistant prostate cancer progressing 
after docetaxel chemotherapy: the role of cabazitaxel in the continuum of care. Eur Urol. 2012;62:1201-4.
12. Oudard S, de Bono JS, Ozguroglu M, et al. Impact of cabazitaxel + prednisone on overall survival at 2 years 
and in patients with aggressive disease: post-hoc analyses of TROPIC trial. Ann Oncol. 2012;23 (suppl 9; 
abstr 933).
13. Buonerba C, Pond GR, Sonpavde G, et al. Potential value of Gleason score in predicting the benefit of 
cabazitaxel in metastatic castration-resistant prostate cancer. Future Oncol. 2013;9:889-97.
14. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic 
castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. 
Lancet. 2010;376:1147-54.
15. Armstrong AJ, Garrett-Mayer E, Ou Yang YC, et al. Prostate-specific antigen and pain surrogacy analysis in 
metastatic hormone-refractory prostate cancer. J Clin Oncol. 2007;25:3965-70.
16. Epstein JI, Allsbrook WC, Jr., Amin MB, Egevad LL, Committee IG. The 2005 International Society of Urological 
Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 
2005;29:1228-42.
17. Montironi R, Cheng L, Lopez-Beltran A, et al. Original Gleason system versus 2005 ISUP modified Gleason 
system: the importance of indicating which system is used in the patient’s pathology and clinical reports. 
Eur Urol. 2010;58:369-73.
18. Billis A, Guimaraes MS, Freitas LL, et al. The impact of the 2005 international society of urological pathology 
consensus conference on standard Gleason grading of prostatic carcinoma in needle biopsies. J Urol. 
2008;180:548-52.
19. Laitinen S, Martikainen PM, Tolonen T, et al. EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy 
treated patients. Int J Cancer. 2008;122:595-602.
20. Mitra AV, Jameson C, Barbachano Y, et al. Elevated expression of Ki-67 identifies aggressive prostate cancers 
6
92
but does not distinguish BRCA1 or BRCA2 mutation carriers. Oncol Rep. 2010;23:299-305.
21. Miyake H, Muramaki M, Kurahashi T, Takenaka A, Fujisawa M. Expression of potential molecular markers 
in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical 
prostatectomy. Urol Oncol. 2010;28:145-51.
22. Alba E, Calvo L, Albanell J, et al. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment 
in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II 
study. Ann Oncol. 2012;23:3069-74.
23. Warm M, Kates R, Grosse-Onnebrink E, et al. Impact of tumor biology, particularly triple-negative status, on 
response to pre-operative sequential, dose-dense epirubicin, cyclophosphamide followed by docetaxel in 
breast cancer. Anticancer Res. 2010;30:4251-9.
24. Jacquemier J, Boher JM, Roche H, et al. Protein expression, survival and docetaxel benefit in node-positive 
breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial. Breast Cancer 
Res. 2011;13:R109.
25. Li XR, Liu M, Zhang YJ, et al. Evaluation of ER, PgR, HER-2, Ki-67, cyclin D1, and nm23-H1 as predictors of 
pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer. Med 
Oncol. 2011;28 Suppl 1:S31-8.
6
93
``
``
CHAPTeR 7
NeuTRoPHil To lyMPHoCyTe RATio As A 
PRoGNosTiC bioMARkeR foR MeN wiTH MeTAsTATiC 
CAsTRATioN-ResisTANT PRosTATe CANCeR 
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Two RANdoMized PHAse iii TRiAls
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Guru Sonpavde, Eitan Amir, Bertrand Tombal, Mark Rosenthal, Mario A. Eisenberger, Ian F. 
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aBsTraCT
Background: The neutrophil to lymphocyte ratio (NLR), a marker of host inflammation, 
has been associated with poor outcome in several solid tumors. Here, we investigated 
associations of the derived NLR (dNLR) and duration of initial androgen deprivation 
therapy (ADT) with survival of men with metastatic castration-resistant prostate cancer 
(mCRPC) receiving first-line chemotherapy.
patients and methods: Data from the multinational randomized phase III studies VENICE 
and TAX327 included a total of 2230 men with mCRPC randomized to receive first-line 
chemotherapy, and were used as training and validation sets respectively. Associations of 
dNLR and duration of initial ADT with OS were evaluated by multivariable Cox regression 
analysis in the training set stratified for performance status and treatment arm. The model 
was then tested in the validation set. Subsequently we investigated the treatment effect 
of docetaxel on OS in subgroups according to dNLR and duration of initial ADT.
results: In the training set both dNLR ≥median (2) and duration of initial ADT <median (15 
months) were associated with increased risk of death (HR=1.29;95%CI: 1.11-1.50, P<0.001 
and HR=1.41; 95%CI: 1.21-1.64, P<0.001 respectively) after adjustment for age, alkaline 
phosphatase, hemoglobin, and pain at baseline. In the validation set, dNLR remained 
an independent prognostic factor for OS (HR=1.43; 95%CI: 1.20-1.70, P<0.001), whereas 
duration of initial ADT was not (HR=1.16; 95%CI: 0.97-1.37, P=0.10). In subgroup analyses 
of the TAX327 study, docetaxel improved OS irrespective of dNLR and duration of initial 
ADT. 
Conclusion: The dNLR was prognostic for OS in men with mCRPC receiving first-line 
chemotherapy in two randomized phase III trials. A high dNLR (≥2) was associated with 
shorter survival irrespective of the received treatment. This readily available biomarker 
may serve for risk stratification in future clinical trials and could be incorporated into 
prognostic nomograms.
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inTroduCTion
Treatment options for men with metastatic castration-resistant prostate cancer 
(mCRPC) have expanded with the introduction of several new approved agents including 
abiraterone, enzalutamide, cabazitaxel and radium-223 [1]. Docetaxel with prednisone is 
the standard first-line chemotherapy and has shown to improve survival and its quality as 
compared with mitoxantrone in the TAX327 study [2]. Many trials have been conducted 
to investigate whether the efficacy of docetaxel could be improved by adding a targeted 
agent. The VENICE study was a randomized phase III trial that investigated the combination 
of docetaxel and aflibercept, a recombinant human fusion protein that binds A and B 
isoforms of vascular endothelial growth factor and placental growth factor [3]. Median 
overall survival (OS) was similar in the two arms of the trial.
With evidence that both abiraterone and enzalutamide are effective agents when 
administered to men with mCRPC either before or after chemotherapy [1,4,5], treatment 
selection and sequencing for an individual patient has become more challenging. 
Therefore, prognostic and predictive biomarkers for response to the various drugs 
approved for treatment of mCRPC are needed to guide clinical practice and trial design. An 
elevated neutrophil to lymphocyte ratio (NLR), a marker for host inflammation, was found 
to be an independent marker of adverse outcomes for several solid tumors including 
mCRPC [6-8]. In men with mCRPC treated with abiraterone, NLR ≥5 was associated with 
lower PSA response rates and shorter survival [9]. Since peripheral blood contains few 
white cells other than neutrophils or lymphocytes, a derived NLR (dNLR) calculated by the 
absolute neutrophil count divided by the difference between white cell and neutrophil 
counts, approximates NLR and has demonstrated similar prognostic value to the NLR [10].
Another potential prognostic factor in men with mCRPC, the duration of previous 
androgen deprivation therapy (ADT), was incorporated in a prognostic nomogram for men 
receiving second-line chemotherapy [11]. A longer duration of ADT was also associated 
with favorable outcomes in men treated with abiraterone in the post-docetaxel setting [12]. 
The implications of both dNLR and duration of initial ADT for men receiving first-line 
chemotherapy are unknown.
In this analysis, we used data from two randomized phase III studies to investigate the 
prognostic value of the dNLR and duration of initial ADT in men with mCRPC receiving 
first-line chemotherapy. We hypothesized that an elevated dNLR and shorter duration of 
initial ADT are associated with shorter survival. As a secondary objective, we aimed to 
investigate whether dNLR and duration of initial ADT were able to predict the treatment 
effect of docetaxel on OS and PSA response.
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paTienTs and MeThods
study population
For this study we used the VENICE study as a training set and the TAX327 study as 
an independent validation cohort [2,3]. These two large trials provided independent 
databases with mCRPC patients receiving first-line chemotherapy.
The VENICE study was a multinational phase III trial conducted in 1224 men with 
mCRPC who were treated with docetaxel (75 mg/m²) every 3 weeks plus prednisone 
(10 mg daily) (D3) and were randomized to receive aflibercept (6 mg/kg) or placebo [3]. 
TAX327 was a multinational randomized phase III study involving 1006 men with mCRPC, 
who were randomized to receive D3, weekly docetaxel (30 mg/m²) (D1) or 3-weekly 
mitoxantrone (12.5 mg/m²) (M), each with prednisone. Full details of the VENICE and 
TAX327 trials are provided in the original reports [2,3]. Both studies were approved by an 
institutional review board at each participating institution. Written informed consent was 
obtained from all participants.
data collection and definitions
The primary objectives of this study were to explore the prognostic role of the dNLR 
and the duration of initial ADT on OS, as defined by time from randomization to death 
from any cause.  As a secondary objective we investigated treatment effects of docetaxel 
on OS and PSA response according to dNLR and the duration of initial ADT. 
The variables that were considered for the prognostic model are shown in 
Supplementary table S1 and included among others; metastatic site, pain at baseline, 
baseline PSA, PSA doubling time, baseline testosterone, alkaline phosphatase, and 
hemoglobin [13]. The dNLR was calculated from peripheral blood counts as neutrophils 
divided by the difference of leukocytes and neutrophils. The duration of initial ADT was 
defined as the time from start of first-line hormonal therapy, (i.e.LHRH agonists, LHRH 
antagonists, surgical castration, with or without the addition of anti-androgens) to the 
start date of first subsequent anticancer treatment. Adjuvant hormonal therapy and anti-
androgens given for short period to avoid PSA flare were not considered.
Model building and statistical considerations
We conducted univariable and multivariable Cox regression analyses in our training 
set (VENICE), stratified for ECOG performance status (0-1 vs 2) and treatment arm as 
was done in the initial study. The multivariable model was constructed using backward 
elimination at the 5% level. From this multivariable model, a risk score was composed for 
patients with 0-1,2,3,4, and 5-6 risk factors respectively. We performed sensitivity analyses 
using backward elimination without including pain to investigate whether there was any 
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impact of excluding pain data (N=197 missing in training set) on our multivariable model
The dNLR and duration of initial ADT were dichotomized according to their medians 
to make our results more generalizable. For supportive analyses dNLR and duration of 
initial ADT were studied by calculating the area under receiver operating characteristic 
curves (AUC) to identify optimal cutoffs with the end point dead or alive at month 24. 
Baseline laboratory variables were dichotomized using the median value. 
validation
The TAX327 database including all randomized men was used to externally validate 
and test the prognostic factors and prognostic score identified from the training set. The 
analysis was stratified for Karnofsky performance status (≤70 vs ≥80) and treatment arm [2]. 
Cutoffs were defined by the medians of the training set.
The statistical analyses for model development and validation were carried out using 
SAS version 9.2 (SAS Institute, Cary, NC). All statistical tests were two sided, and statistical 
significance was defined as P<0.05. Since this was an exploratory analysis, no correction 
for multiple testing was applied.
Treatment effect of docetaxel according to dnlr and duration of initial adT
We used subgroup analyses to investigate whether dNLR and duration of initial ADT 
were able to predict the treatment effect of docetaxel on OS and PSA response. The 
TAX327 database was used to investigate OS benefit and PSA response in men receiving 
D3 as compared to the M control arm in subgroups of dNLR ≥median and <median, and 
in subgroups defined by duration of initial ADT ≥median and <median. The D1 arm was 
not included in the subgroup analyses, since D3 is the approved standard docetaxel 
regimen. To test whether there were differences in baseline variables known to predict OS 
between D3 and M in the defined subgroups, we used Fisher’s exact test for all categorical 
variables, and the Wilcoxon Rank Sum test for all continuous variables. OS for D3 and M in 
the subgroups of dNLR and duration of initial ADT was assessed using the Kaplan-Meier 
method with statistical evaluation by the logrank test. 
Confirmed PSA response, defined according to the Prostate Cancer Working Group 2 
criteria was evaluated in subgroups of dNLR and duration of initial ADT in both TAX327 
and VENICE databases, with statistical evaluation using Fisher’s exact test. We used 
logistic regression with backward elimination adjusted on baseline PSA, and stratified 
for performance status and treatment arm to construct a model for the prediction of a 
confirmed PSA response (≥50%) in the VENICE database, with validation in TAX327.
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resulTs 
Baseline characteristics 
Baseline characteristics of the training and validation sets were generally well 
comparable (table 1). Median OS was 21.1 and 19.2 months for men treated with D3 in the 
VENICE and TAX327 studies respectively [2,3]. 
The median dNLR was 2.0 in the training set and 2.1 in the validation set, and the 
median duration of initial ADT was 15 months in both datasets. The optimal threshold 
for the prediction of OS by ROC-analysis in the training set was 2.05 for dNLR (AUC 0.58), 
which was almost identical to the median. For the duration of initial ADT the optimal 
threshold for the prediction of OS in the training set was 13.5 months (AUC 0.58). 
Table 1. Baseline characteristics of men in the training and validation sets.
Characteristic veniCe Tax327
Number of patients randomized 1224 1006
Age, years, median (range) 68 (40-88) 68 (36-92)
Missing 0 0
Performance score n (%)
ECOG 0–1 1170 (95.6%)
2 54 (4.4%)
Missing 0
Karnofsky
≥80 875 (87.1)
≤70 130 (12.9)
Missing 1
Metastatic site n (%)
Visceral 347 (28.4) 229 (22.9)
Bone with no visceral involvement 800 (65.4) 720 (72.1)
Lymph node only 76 (6.2) 50 (5.0)
Missing 1 7
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PSA, ng/ml, median (range) 86.8  (0-6138) 114 (0-40740)
Missing 1 2
Pain at baseline n (%) 366 (35.6) 458 (45.8)
Missing 197 6
Hemoglobin at baseline, g/dl, median 
(range)
12.7 (7.9-16.4) 12.7 (6.4-16.3)
Missing 0 0
Alkaline phosphatase at baseline, IU/L, 
median (range)
142 (20-6498) 205 (18-9900)
Missing 7 0
dNLR, median (range) 2.0 (0.2-19.4) 2.1 (0.3-19)
Missing 6 5
Duration of initial ADT, median, months, 
(range)
15.0 (2-272) 15.4 (0-226)
Missing 5 2
PSA, prostate-specific antigen; dNLR, Derived neutrophil to lymphocyte ratio; ADT, 
Androgen deprivation therapy
associations of dnlr and duration of initial adT with survival in the training set
In multivariable analysis of the training set, both dNLR ≥median and a duration of 
ADT <median were associated with an increased risk of death (HR=1.29; 95%CI: 1.11–1.50, 
P<0.001 and HR=1.41; 95%CI: 1.21–1.64, P<0.001 respectively) after adjustment for age, 
alkaline phosphatase, hemoglobin, and pain at baseline. The final multivariable model for 
the prediction of OS constructed in the training set is shown in table 2. Sensitivity analyses 
without including pain resulted in selection of the same variables, demonstrating that 
there was no impact on our multivariable model of excluding pain data (N=197 missing 
in training set). Univariable analyses of all considered variables such as baseline PSA, PSA 
doubling time, metastatic site, and baseline testosterone in the training set are shown in 
Supplementary table S1. 
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Table 2. Multivariable model for OS in the training and validation sets.
Training (veniCe) validation (Tax327)
variable
hazard ratio
P-value
hazard ratio
P-value
(95% Ci)  (95% Ci)
Age ( ≥median) 1.24 (1.06-1.44) 0.006 1.02 (0.86-1.22) 0.82
Alkaline Phosphatase at baseline 
(≥median)
1.65 (1.41-1.93) <0.001 1.43 (1.18-1.74) <0.001
Duration of initial ADT (<median) 1.41 (1.21-1.64) <0.001 1.16 (0.97-1.37) 0.10
dNLR (≥median) 1.29 (1.11-1.50) <0.001 1.43 (1.20-1.70) <0.001
Hemoglobin at baseline (<median ) 1.45 (1.24-1.69) <0.001 1.38 (1.16-1.65) <0.001
Pain at baseline (PPI >=2) 1.56 (1.33-1.82) <0.001 1.59 (1.33-1.90) <0.001
ADT, androgen deprivation therapy; dNLR, derived neutrophil to lymphocyte ratio; PPI, Present Pain 
Intensity Scale from the McGill-Melzack questionnaire
Survival curves according to dNLR in the training set are shown in Figure 1 A, with 
an OS of 26.0 months (95%CI: 23.8–27.8) for men with a dNLR <median and 19.1 months 
(95%CI: 17.7–20.2) for men with a dNLR ≥median (logrank P<0.001). Men with a duration 
of initial ADT <median had an OS of 18.8 months (95%CI: 17.7–20.2) as compared to 
25.0 months (95%CI: 23.6–27.2) for a duration of initial ADT ≥median (logrank P<0.001) 
(Supplementary figure S1 A). 
Four risk groups were composed for men with 0-1,2,3,4, and 5-6 risk factors from 
the multivariable model in the training set. Outcomes according to these risk groups 
are shown in Supplementary table S2 and Supplementary figure S2 A. The risk score was 
significantly and inversely associated with OS (P<0.001).
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figure 1. Kaplan-Meier estimates of overall survival in men with dNLR  ≥median and <median in the training set (A) and in 
thevalidation set using the median as defined in the training set (B).
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validation
Testing the final model in the validation set showed that dNLR remained an 
independent prognostic factor for OS with a HR of 1.43 for men with a dNLR ≥2.0 (95%CI: 
1.20–1.70, P<0.001), whereas duration of ADT was not independently associated with OS 
(HR=1.16; 95%CI: 0.97–1.37, P=0.10) (table 2).
Median OS was 19.8 months (95%CI: 18.7–21.6) versus 15.7 months (95%CI: 14.4–17.2) 
respectively for men with a dNLR  <2.0 versus ≥2.0 in the validation set (logrank P<0.001) 
(Figure 1B). In men with a duration of initial ADT <15 months median OS was 16.8 months 
(95%CI: 15.1–17.6) as compared to 19.2 months (95%CI 17.4–20.9) for men with a duration 
of initial ADT ≥15 months (logrank P=0.06) (Supplementary figure S1 B).  The composed 
risk score derived from the training set was also significantly associated with OS in the 
validation set (P<0.001) (Supplementary table S2 and Supplementary figure S2 B). 
Treatment effect of docetaxel on os and psa response according to dnlr and 
duration of initial adT
In the TAX327 database, baseline characteristics including known prognostic factors were 
similar among subgroups of dNLR (≥median and <median) and duration of initial ADT (≥median 
and <median) (Supplementary table S3). Comparing men treated with D3 versus M in subgroups 
according to dNLR and duration of initial ADT, the risk reduction of death consistently favored 
the D3 arm (table 3). No significant interaction of dNLR and duration of initial ADT on the 
treatment effect of D3 versus M on OS was observed (P=0.50 and P=0.30 respectively). 
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            The overall rate of confirmed PSA response (≥50%) in men treated with D3 was higher 
in the subgroup with a dNLR <median as compared to ≥median in both TAX327 (70% vs 
53%, P=0.001) and VENICE databases (76% vs. 67% P=0.001) (Table 4). When adjusted for 
other prognostic factors dNLR remained associated with PSA response in a multivariable 
logistic regression model constructed in the VENICE dataset (P=0.009) with validation 
in TAX327 (P<0.001) (Supplementary table S4). PSA response rates were similar among 
subgroups defined by duration of initial ADT (Table 4). 
When assessing the treatment effect of D3 on PSA response, D3 improved PSA 
response rates over M for both dNLR ≥median (53% for D3 versus 36% for M, P=0.002) and 
<median (70% for D3 versus 49% for M, P<0.001). Accordingly, PSA response rates were 
higher for D3 versus M in men with a duration of initial ADT ≥median (60% and 45% for 
D3 versus M respectively, P=0.009) and <median (62% for D3 versus 39% for M, P<0.001).
Table 4. PSA response rates in men treated with D3 according to dNLR and duration of 
initial ADT.
dnlr ≥median dnlr <median
duration of 
initial adT 
≥median
duration of 
initial adT 
<median
Tax327
≥50% PSA decline n(%) 91 (53) 107 (70) 107 (60) 94 (62)
P-value 0.001 0.734
veniCe
≥50% PSA decline n(%) 402 (67) 451 (76) 444 (74) 413 (70)
P-value 0.001 0.122
dNLR, derived neutrophil to lymphocyte ratio; ADT, androgen deprivation therapy PSA, prostate-specific 
antigen
disCussion
In this study we identified and externally validated the prognostic role of dNLR in 
men with mCRPC receiving first-line chemotherapy. A high dNLR (≥2) was associated with 
shorter survival irrespective of the received treatment and other prognostic factors. The 
duration of initial ADT was prognostic for OS in the training set, but did not reach statistical 
significance in the validation set. Both dNLR and duration of initial ADT did not have 
predictive value, as docetaxel improved OS and PSA response in all defined subgroups. 
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To our knowledge, we are the first to identify and validate the prognostic value of dNLR 
in men with mCRPC receiving first-line chemotherapy, using data from two randomized 
phase III trials. The dNLR is a readily available biomarker, which is easy to obtain and 
comes with no extra costs. It may be used for risk stratification in clinical trials, could be 
incorporated in prognostic nomograms, and may give direct prognostic information on 
patients with mCRPC in daily practice.
The prognostic role of NLR has been shown in many solid tumors included in a 
recent meta-analysis of one hundred studies [6]. These observations suggest a broad 
prognostic impact of NLR across different tumor types, disease settings, and treatments. 
Although the exact mechanisms behind the unfavourable prognostic implications of an 
elevated NLR remain to be elucidated, it may relate to increased neutrophil-dependent 
inflammation, and reduced lymphocyte mediated tumor response [14]. Neutrophils are 
able to favour tumor development and inhibit the activity of lymphocytes and other 
immune cells, while the presence of intratumoral lymphocytes is associated with better 
responses to cytotoxic treatment and more favorable prognosis in cancer patients [15]. 
We studied the dNLR instead of the NLR as lymphocyte counts were not available in both 
datasets. Most leukocytes in the peripheral blood are either neutrophils or lymphocytes, 
so that subtraction of neutrophils from the total leukocyte count gives a good estimate of 
the lymphocyte count. It has been confirmed in other studies that dNLR provides similar 
prognostic value to the NLR [10]. 
As a secondary objective of our study we evaluated the treatment effect of docetaxel 
in subgroups according to dNLR. A high NLR has been shown previously to be associated 
with low PSA response rates to abiraterone (16%) and worse OS in patients with mCRPC 
[9]. Here we report that although patients with a high dNLR have an unfavorable 
prognosis, docetaxel provides a robust OS benefit of 4.3 month and ≥50% PSA declines in 
53-67% of this patient group. Although our patient population and the cohort reported 
for abiraterone are not directly comparable, this generates the hypothesis that in 
patients with a high dNLR treatment with chemotherapy might be more beneficial than 
abiraterone. Unfortunately, there is no data to confirm whether NLR is a marker of better 
response to AR-targeted agents or chemotherapy.
Halabi et al. have previously demonstrated the prognostic importance of the duration 
of ADT in patients with mCRPC receiving second-line chemotherapy [11]. The duration 
of ADT was also associated with survival in a prognostic model of men treated with 
abiraterone in the post-docetaxel setting [12]. In our analysis, duration of initial ADT only 
demonstrated independent prognostic value in the training set. We investigated the 
duration of initial ADT as it better approximates the biologically and clinically relevant 
time of actual response to hormonal therapy [16]. ADT by either surgical or hormonal 
castration as defined in our analysis was a mandatory inclusion criterion of both studies. 
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Furthermore, all men included in our analysis continued LHRH agonists/antagonists 
during chemotherapy. As such, the total duration of ADT would not provide a good 
estimate of the response duration. In contrast, the use of additional anti-androgens (e.g. 
bicalutamide) after initial castration was not mandatory and thus highly variable between 
patients. Therefore, use of such drugs was not included in our definition. 
The main strength of our study is the use of two large databases of men with mCRPC 
receiving first-line chemotherapy in randomized phase III studies, as a training set and 
independent validation set. An inherent limitation is its retrospective nature. Also, data were 
not available to allow correction for some known prognostic factors such as baseline levels 
of lactate dehydrogenase (LDH) and albumin [13].  However, previous data investigating 
NLR in men with mCRPC receiving docetaxel showed a significant independent association 
between NLR and OS even after adjustment for LDH and albumin [7]
In conclusion, dNLR was prognostic for OS in men with mCRPC receiving first-line 
chemotherapy in two randomized phase III trials. A high dNLR (≥2) was associated with 
shorter survival irrespective of the received treatment. This readily available biomarker 
may serve for risk stratification in future clinical trials and could be incorporated into 
prognostic nomograms. In addition, it could give direct prognostic information on 
patients in daily practice.
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suppleMenTary TaBles
supplementary table s1. Univariable analyses for OS of all variables considered in the 
training set, stratified for performance status and treatment arm.
              Training (veniCe)
variable
              hazard ratio
P-value
              (95% Ci)
Age ( ≥median) 1.11 (0.97-1.27) 0.120
Metastatic site
Lymph node only Reference 0.002
Bone metastases with no visceral involvement 1.62 (1.18-2.22)
Any visceral metastases 1.83 (1.31-2.54)
Alkaline Phosphatase at baseline (≥median) 2.03 (1.77-2.33) <0.001
Gleason score (8-10 vs. ≤7) 1.08 (0.94-1.23) 0.299
Duration of initial ADT (<median) 1.39 (1.21-1.59) <0.001
Type of progression
PSA only Reference 0.091
Bone scan with no radiologic progression 1.17 (1.01-1.36)
Radiologic progression 1.03 (0.86-1.24)
Prior prostatectomy 0.94 (0.82-1.08) 0.378
Prior radiotherapy 1.05 (0.91-1.21) 0.539
dNLR (≥median) 1.49 (1.30-1.71) <0.001
PSA at baseline (≥median) 1.48 (1.30-1.70) <0.001
PSA doubling time (<median) 1.29 (1.13-1.49) <0.001
Testosterone at baseline (≥median) 1.01 (0.88-1.15) 0.935
Hemoglobin at baseline (<median ) 1.86 (1.63-2.13) <0.001
Pain at baseline (PPI >=2) 1.88 (1.62-2.18) <0.001
dNLR, Derived neutrophil to lymphocyte ratio; PPI, Present Pain Intensity Scale from the McGill-Melzack 
questionnaire
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supplementary table s4. Multivariable logistic regression model for PSA response 
(≥50%) in VENICE, with validation in TAX327.
veniCe Tax327
variable
odds ratio
P-value
odds ratio
P-value
 (95% Ci)  (95% Ci)
Alkaline Phosphatase at baseline (≥median) 0.73 (0.55; 0.99) 0.040 0.69 (0.52-0.91) 0.008
Pain at baseline (PPI >=2) 0.65 (0.48; 0.87) 0.005 0.76 (0.58-1.00) 0.046
dNLR (≥median) 0.68 (0.51-0.91) 0.009 0.56 (0.43-0.73) <0.001
dNLR, Derived neutrophil to lymphocyte ratio; PPI, Present Pain Intensity Scale from the McGill-Melzack 
questionnaire
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suppleMenTary figures
supplementary figure s1. Kaplan-Meier estimates of overall survival in men with a duration of initial ADT ≥median and 
<median in the training set (A) and in the validation set using the median as defined in the training set (B).
 
No.at risk 0 months 6 months 12 months 18 months 24 months 30 months 36 months 
Duration of 
initial ADT 
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supplementary figure s2. Kaplan-Meier estimates of overall survival according to the number of risk factors 
derived from the multivariable model in the training set (A) and in the validation set (B).
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GeNeRAl disCussioN
Partly published in European Urology Today, EAU Annual Congress, 20-24 March 2015
Cross-resisTanCe BeTween Taxanes and new horMonal agenTs and 
poTenTial iMpliCaTions for CliniCal sTudies on TreaTMenT sequenCe
The treatment armamentarium for mCRPC has evolved over the past few years, 
with the introduction of several new approved drugs including cabazitaxel, abiraterone, 
enzalutamide, and radium-223 [1-4]. At the current time, no predictive biomarkers for 
the available treatments exist, and the optimal drug treatment sequence is unknown. 
Treatment decisions are largely based on personal preferences, reimbursement policies, 
and toxicity profiles, as no level 1 evidence to tailor therapy is available. Retrospective 
studies suggested that the overall survival benefits obtained by the new therapies 
cannot be simply added up, as cross-resistance between taxanes and AR-targeted has 
been observed. Therefore, it is of utmost importance to identify the mechanisms of cross-
resistance between the current therapies in mCRPC, in order to determine the optimal 
treatment sequence for individual patients.
Taxanes (i.e. docetaxel, and cabazitaxel) suppress dynamic instability of microtubules 
and alter microtubule polymer mass as their main mechanism of action. Recent reports 
demonstrated that by inhibiting microtubules, paclitaxel and docetaxel also impair AR 
signaling, which in the setting of mCRPC may represent part of their therapeutic efficacy [5, 
6]. In this thesis we have developed CRPC cell lines with acquired resistance to abiraterone 
and enzalutamide to identify and give insight in mechanisms of cross-resistance between 
the currently available therapies: docetaxel, cabazitaxel, abiraterone and enzalutamide. 
We showed that the efficacy of taxanes was reduced in abiraterone- and enzalutamide-
resistant cells. Of note, the efficacy of abiraterone was reduced in enzalutamide-resistant 
cells and vice versa. These observations are exactly concordant with retrospective clinical 
studies suggesting a degree of cross-resistance between these drugs, reflecting the clinical 
relevance of our cell line model [7-11]. Thus far, the clinical studies that have reported on 
cross-resistance between mCRPC treatments have all been retrospective, with the risk of 
potential selection bias. The major strength of our cell line model is that it enables us to 
study CRPC and mechanisms of cross-resistance under standardized conditions, in well-
defined patient-derived cells.
Subsequently, we showed that docetaxel, cabazitaxel, abiraterone and enzalutamide 
all act on AR nuclear transport, which is a crucial step in AR signaling, and provide 
a mechanistical explanation for cross-resistance between taxanes and the novel AR 
targeting agents abiraterone and enzalutamide. It has been reported by other groups that 
AR transport is facilitated by microtubules and the motor protein dynein, which explains 
the inhibitory effects of taxanes on the AR [5, 6, 12, 13]. Interestingly, the inhibiting effects 
on the AR by abiraterone were observed in the presence of the synthetic androgen R1881, 
suggesting that abiraterone might be able to directly inhibit the AR, independent of 
CYP17A1 inhibition. This was also shown by Richards et al., who found that abiraterone 
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is able to bind and inhibit the AR at high but clinically relevant concentrations (≥5 uM). 
As a next step, we confirmed our findings of cross-resistance between docetaxel 
and enzalutamide in an in vivo model of CRPC. Docetaxel efficacy was impaired in 
enzalutamide-resistant tumors (PC346Enza), as compared to enzalutamide-naïve tumors 
(PC346C), demonstrating in vivo cross-resistance between these drugs. As a mechanism 
for our observed cross-resistance, we showed that docetaxel efficiently impaired AR 
nuclear localization and consequently AR regulated gene expression in enzalutamide-
naïve tumors, while it did not in enzalutamide-resistant tumors. The role of microtubules in 
AR transport and the resulting inhibitory effects of docetaxel on the AR have only recently 
been elucidated [13, 14]. In the present thesis we demonstrated that the reduced inhibition 
of docetaxel on the AR in enzalutamide-resistant tumors confers cross-resistance between 
these drugs in vivo. These results indicate that the inhibitoiry effects of docetaxel on the 
AR represent part of its antitumor activity, which is impaired by previous AR targeted 
therapy such as enzalutamide. In this light, it could also explain the reduced efficacy of 
docetaxel when used after prior treatment with abiraterone observed in retrospective 
clinical studies [9, 15, 16]. Ultimately, the proof of cross-resistance and the consequences 
for treatment sequencing should be investigated in prospective randomized trials. Such 
studies could investigate the sequence of docetaxel followed by AR-targeted therapy or 
vice versa, as well as AR-targeted therapy followed by AR targeted therapy versus a taxane. 
It will however take years to conduct these studies, and it is uncertain whether such a trial 
would provide definitive answers in the current treatment landscape. With an abundance 
of both approved and experimental therapies, subsequent treatments are likely to have a 
confounding effect on survival outcomes. Recently, the promising and biologically active 
drug orteronel (TAK-700) failed to demonstrate a survival benefit at least in part due to 
confounding effects of cross-over in the control arm of the study [17, 18]. 
In our in vivo model of enzalutamide-resistant CRPC we found superior efficacy of 
cabazitaxel as compared to treatment with docetaxel. Cabazitaxel demonstrated robust 
tumor and PSA responses in our enzalutamide-resistant xenografts, while the effects on 
AR signaling were reduced as compared to those in enzalutamide-naïve tumors. These 
observations indicate that cabazitaxel is less dependent on its inhibitory effects on the 
AR pathway, and exerts greater antitumor activity via AR independent mechanisms as 
compared to docetaxel. This sustained efficacy is concordant with clinical observations 
[19, 20], and is probably caused by a higher potency of cabazitaxel to suppress microtubule 
dynamics as compared to docetaxel, with faster drug uptake and better intracellular 
retention [21]. These superior properties of cabazitaxel were best reflected in our in vivo 
experiments as compared to the in vitro experiments, which is probably caused by the lack 
of a three dimensional tumor representation of an in vitro system. The greater potency 
of cabazitaxel after AR-targeted treatment might have clinical implications, as currently 
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docetaxel is the standard first-line chemotherapy for men with mCRPC. Considering the 
superior efficacy of cabazitaxel over docetaxel in our enzalutamide-resistant tumors, 
these results provide a rationale for clinical studies comparing cabazitaxel with docetaxel 
in men with mCRPC who progressed on first-line enzalutamide or abiraterone. 
The question whether cabazitaxel is superior to docetaxel as first line-treatment for 
mCRPC is currently addressed in the FIRSTANA study (NCT01308567) which compares 
cabazitaxel 25 mg/m2 and cabazitaxel 20 mg/m2 both with prednisone, to docetaxel 75 
mg/m2 plus prednisone. The study has completed accrual and results are expected in 
2016.
In the present thesis, we aimed to clinically confirm our preclinical findings of 
sustained cabazitaxel efficacy after prior treatment with novel AR-targeted therapie. 
Therefore, we used data from a prospective, multicenter, randomized phase II trial 
(CABARESC) to compare the clinical outcome of patients receiving cabazitaxel with and 
without prior abiraterone or enzalutamide treatment. Concordant with our preclinical 
findings, we demonstrated in patients that prior novel AR-targeted therapy did not affect 
the efficacy of cabazitaxel. These results clinically confirmed that cabazitaxel provides a 
good treatment option both before and after novel AR-targeted therapies in the post-
docetaxel setting. It also shows that cabazitaxel has truly different properties as compared 
to docetaxel, which has been shown to loose part of its efficacy when used after novel 
AR-targeted therapy [15,16].
Future efforts in mCRPC are currently focusing on combination therapy. The efficacy 
of abiraterone plus enzalutamide is currently evaluated as compared with enzalutamide 
alone in a randomized phase III trial of chemotherapy-naïve mCRPC patients 
(NCT01949337). The rationale for this combination is an observed increased androgen 
synthesis in patients treated with enzalutamide [22]. This could theoretically result in 
competition between enzalutamide and testosterone at the level of the AR [23]. On the 
other hand, increasing AR copy numbers were observed in tumors of patients treated 
with abiraterone [24]. Combining the two drugs could potentially inhibit these adaptive 
feedback mechanisms. 
In the absence of prospective studies on the treatment sequence, clinicians should 
be aware of potential cross-resistance between the available therapies. Novel AR targeted 
agents abiraterone and enzalutamide have proven to be very effective agents either when 
delivered before or after docetaxel chemotherapy. However, since all available studies 
consistently point to reduced efficacy of docetaxel when used after abiraterone, clinicians 
should beware that cross-resistance might occur when treating patients with hormonal 
agents before docetaxel. Also, sequential treatment with AR-targeted agents could be a 
strategy that potentially leads to cross-resistance. In this treatment continuum there might 
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be an important role for cabazitaxel, for which there is no evidence of cross-resistance with 
the other therapies in mCRPC. In this thesis we showed that although cabazitaxel is able to 
inhibit AR nuclear translocation, it exhibits superior antitumor activity independent of the 
AR pathway in both preclinical and clinical studies. Since cross-resistance might develop 
by subsequently targeting the AR, cabazitaxel may very well become to future taxane of 
choice in patients with progressive disease on either abiraterone or enzalutamide. 
In summary, there has been major progress in the treatment of mCRPC over the past 
few years. The current challenge is how to sequence these drugs, and to deliver them to 
the patients that will benefit. Ultimately, biomarkers for response to the various treatment 
options may facilitate treatment decisions. Our findings of cross-resistance presented 
here provide a mechanism for reduced docetaxel efficacy in enzalutamide-resistant 
prostate cancer. It also explains observations of cross-resistance between abiraterone 
and enzalutamide when used in sequence. Rather than randomly sequencing agents 
based on the way of administration (oral vs. intravenous), or toxicity profiles, efforts 
should be taken to avoid cross-resistance that might occur when delivering docetaxel 
after hormonal agents or repeatedly targeting the AR pathway. Cabazitaxel might prove 
a valuable treatment option here without concerns for cross-resistance. Based on the 
results presented in this thesis and retrospective clinical data, randomized controlled 
trials should further evaluate the treatment sequence.
prediCTive and prognosTiC faCTors in MCrpC paTienTs reCeiving 
doCeTaxel
With evidence that both abiraterone acetate and enzalutamide are effective agents 
when administered to men with mCRPC either before or after chemotherapy [1, 3, 25, 
26], treatment selection and sequencing for an individual patient has become more 
challenging. Since no predictive biomarkers for the available treatments exist at the 
current time, it is unknown which patient will benefit from which treatment. Therefore, 
predictive biomarkers for response to the various drugs approved for treatment of 
mCRPC are needed to guide clinical practice and trial design. Since prospective studies 
of established predictive biomarkers facilitating treatment decisions are largely lacking, 
we herewith provide an overview of potential predictive factors to the currently available 
treatment options in mCRPC.
gleason score
In this thesis, we aimed to identify subgroups of patients who derive the greatest 
benefit from docetaxel chemotherapy. A post-hoc analysis of the TAX327 study was 
performed and showed that the overall survivial (OS) benefit obtained by docetaxel 
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was most pronounced in men with high Gleason score tumors (OS benefit 4.4 months 
versus 2.9 months in the whole patient population). At the same time, a high Gleason 
score (8–10) at the time of diagnosis had been reported to be an independent risk factor 
for poor response to abiraterone [27]. These findings suggested a potential predictive 
role of Gleason score. However, although the OS benefit in the COU-AA-302 study of 
abiraterone pre-chemotherapy was less pronounced in patients with high Gleason score 
tumors (7-10), the clinical benefit of abiraterone as assessed by radiographic progression-
free survival demonstrated to be irrespective of Gleason score [28]. Similarly, a post-hoc 
analysis of the TROPIC trial investigating cabazitaxel versus mitoxantrone has shown 
that also cabazitaxel provided clinical benefit regardless of the tumor grading at initial 
diagnosis [29].Thus, Gleason score could be useful in identifying patients who derive the 
most benefit from docetaxel chemotherapy, but might be of less value to predict benefit 
from other treatments.
duration of response to initial adT
An interesting retrospective study of 108 mCRPC patients who received hormonal 
agents including abiraterone in clinical trials demonstrated that patients with a short 
response to prior androgen deprivation therapy (ADT) (<16 months) had poor PSA 
responses and PFS [30]. These findings suggested that patients who progress rapidly 
to castration-resistant disease, with short responses to prior ADT, might do worse on 
consecutive hormonal treatments. In contrast, we performed post-hoc analyses of 2 large 
phase III trials of patients with mCRPC receiving docetaxel, and showed that the treatment 
benefit was irrespective of duration of initial ADT. Likewise, cabazitaxel improved OS 
regardless of duration of initial ADT [29]. Prospective validation of these findings for the 
various compounds approved for the treatment of mCRPC should define whether duration 
of response to prior ADT could be a good parameter for further personalizing treatment.
neutrophil to lymphocyte ratio
The neutrophil to lymphocyte ratio (NLR) is an emerging marker for systemic 
inflammation in cancer. NLR demonstrated independent prognostic value in several solid 
tumors including hepatocellular, gastric, renal cell and colorectal cancer [31-36]. In this 
thesis, we explored the prognostic and predictive role of the neutrophil to lymphocyte 
ratio (NLR) in two multinational randomized phase III trials of mCRPC patients receiving 
first-line chemotherapy. We identified and externally validated dNLR as an independent 
prognostic factor for OS. Men with an elevated dNLR (≥2) had a shorter survival irrespective 
of the received treatment and other prognostic factors (HR 1.29, P<0.001 in training set 
and 1.43, P<0.001 in validation set). Although men with an elevated dNLR had a worse 
prognosis, docetaxel provided a substantial OS benefit of 4.3 months and PSA response 
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rates of 53-67% in this patient population. Of note, a recent study exploring the role of NLR 
in mCRPC patients treated with abiraterone revealed that men with an elevated NLR had 
low PSA response rates (16%) and shorter survival. Taken together, these findings indicate 
that dNLR is useful as a prognostic marker in men receiving first-line chemotherapy. The 
dNLR is not predictive of response in men treated with docetaxel, but might be in men 
receiving abiraterone. Further research should define whether NLR could be a marker of 
better response to AR-targeted agents or chemotherapy.
This readily available biomarker may serve for risk stratification in future clinical 
trials and could be incorporated into prognostic nomograms. In addition, it may provide 
direct prognostic information on patients in daily practice. The prognostic implications 
of systemic inflammation and NLR also provide a rationale for the evaluation of anti-
inflammatory therapy in cancer. A retrospective study in women who underwent 
resection of a primary breast tumor revealed that intraoperative administration of an non-
steroidal anti-inflammatory drug (NSAID) provided better outcome, which was even more 
pronounced in women with en elevated NLR [44].
The prognostic role of NLR has been shown in many solid tumors included in a recent 
meta-analysis of one hundred studies [35]. These observations suggest a broad prognostic 
impact of NLR across different tumor types, disease settings, and treatments. Although the 
exact mechanisms behind the unfavourable prognostic implications of an elevated NLR 
remain to be elucidated, it may relate to increased neutrophil-dependent inflammation, 
and reduced lymphocyte mediated tumor response [37, 38]. Neutrophils are able to 
favour tumor development and inhibit the activity of lymphocytes and other immune 
cells [39, 40], while the presence of intratumoral lymphocytes is associated with better 
responses to cytotoxic treatment and more favorable prognosis in cancer patients [41-43]. 
 
ar splice variants: arv7
The AR splice variant 7 lacks the ligand-binding domain, and remains 
constitutively active in the absence of ligand. ARv7 expression develops in the course of 
disease progression, and is more likely to occur in patients with more advance disease, 
and previous treatment with abiraterone or enzalutamide. A well designed, prospective 
study by Antonarakis et al. showed that men expressing ARv7 in circulating-tumor cells 
did not respond to treatment with either abiraterone or enzalutamide [45]. Also, clinical/
radiographic progression-free survival and OS were inferior in men expressing ARv7. 
Although these findings require large scale validation, it is a promising first step towards a 
more personalized treatment approach in mCRPC, where ARv7 expression in circulating-
tumor cells might be used to facilitate treatment decisions. Future research efforts should 
define the role of Arv7 in resistance versus sensitivity to taxane chemotherapy.
Taken together, with a rapid evolvement of the treatment landscape for mCRPC, 
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predictive biomarkers for the current treatment options are urgently needed. At this 
time, ARv7 expression in circulating-tumor cells is the most promising biomarker for 
future treatment selection. Other potential patient factors that might facilitate treatment 
decisions are derived from retrospective analyses and should therefore be interpreted 
with care. However, in the absence of prospectively derived biomarkers, duration of 
response to previous hormonal therapy and NLR are clinical parameters that are readily 
available, and might give some guidance when treating patients with mCRPC.
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The treatment landscape of metastatic castration-resistant prostate cancer (mCRPC) 
has changed dramatically over the past few years, with the introduction of several new 
approved drugs including cabazitaxel, abiraterone, enzalutamide, and radium-223 [1-5]. 
This considerable progress also comes with new challenges. Concerns of cross-resistance 
between the taxanes (i.e. docetaxel and cabazitaxel) and androgen receptor (AR)-targeted 
agents have arisen, and the optimal drug treatment sequence is still undetermined. There 
is increasing evidence for a reduced efficacy of docetaxel in men with mCRPC who had 
previously been treated with abiraterone, suggesting clinical cross-resistance in several 
retrospective studies [6-8]. Moreover, only modest efficacy have been reported in studies 
investigating abiraterone when used after enzalutamide and vice versa [9-12]. 
Taxanes act through microtubule interaction and polymerization inducing mitotic 
arrest and apoptosis. Recent reports demonstrated that paclitaxel and docetaxel also 
impair AR-nuclear translocation and consequently AR signaling, which in the setting of 
mCRPC might be responsible for part of their therapeutic efficacy [13, 14]. In chapter 
3, castration-resistant prostate cancer (CRPC) cell lines with acquired resistance to 
abiraterone and enzalutamide were developed and used to identify and provide insight 
in mechanisms of cross-resistance between docetaxel, cabazitaxel, abiraterone and 
enzalutamide. In these cell lines, we observed cross-resistance between the taxanes and 
AR targeted agents abiraterone and enzalutamide. As a potential mechanism for our 
observed cross-resistance, we identified the inhibition of AR nuclear translocation as an 
overlapping working mechanism between these drugs. The role of microtubules and 
the motor protein dynein in AR transport have only recently been elucidated [15, 16]. In 
our study, we showed that taxanes are able to inhibit microtubule mediated AR nuclear 
translocation as an additional mechanism of action. This effect was also observed for 
the novel AR targeted agents abiraterone and enzalutamide, identifying an overlapping 
working mechanism that potentially confers cross-resistance between the taxanes and 
novel AR targeted agents.  
In chapter 4 we confirmed our findings of cross-resistance between docetaxel 
and enzalutamide in a mouse model of enzalutamide-resistant versus enzalutamide-
naïve CRPC. Docetaxel efficacy was reduced in tumors with acquired resistance to 
enzalutamide (PC346Enza) as compared to enzalutamide-naïve tumors (PC346C). 
This impaired efficacy of docetaxel was caused by a reduced inhibition of AR nuclear 
localization and consequently AR regulated gene expression in enzalutamide-resistant 
tumors as compared to enzalutamide-naïve tumors. In contrast to docetaxel, cabazitaxel 
remained highly effective in enzalutamide-resistant xenografts, demonstrating greater 
antiproliferative properties independent of the AR pathway. These findings are especially 
of interest, since it is exactly concordant with clinically observed cross-resistance for 
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docetaxel, but not cabazitaxel, [6, 7, 9, 10], which can be mechanistically explained by the 
findings in our xenograft studies.
In chapter 5 we clinically confirmed the findings from our preclinical in vivo 
studies (chapter 4). We used data from a prospective, multicenter, randomized phase II 
study to investigate the influence of prior novel AR-targeted therapies abiraterone and 
enzalutamide on the efficacy of cabazitaxel. We found that PSA response rates (≥50%) 
while on cabazitaxel treatment were similar in patients with and without prior novel AR-
targeted therapy (34% versus 40% respectively, P=0.53). Likewise, median OS was not 
significantly different between men with and without prior novel AR-targeted therapy, 
with a median OS of 9.8 months versus 10.6 months respectively (logrank P=0.65). 
These findings strongly suggest that there is no cross-resistance between abiraterone or 
enzalutamide and cabazitaxel.
In chapter 6 we aimed to identify subgroups of patients who derive the greatest 
benefit from docetaxel chemotherapy. A post-hoc analysis of the TAX327 registration 
study was performed and showed that the clinical benefit obtained by docetaxel was most 
pronounced in men with high Gleason score tumors. Median OS in men with high Gleason 
score tumors (7-10) was 4.4 months (logrank P=0.009), as compared to 2.9 months in the 
whole patient population. In a time of shifting paradigms in mCRPC with AR targeted 
agents available prior to docetaxel chemotherapy, Gleason score may help in selecting 
patients who obtain the greatest benefit from docetaxel as first-line treatment for mCRPC.
The neutrophil to lymphocyte ratio (NLR) is a marker for systemic inflammation, 
which is one of the emerging hallmarks of cancer [17]. In chapter 7 we explored the 
prognostic and predictive role of the derived neutrophil to lymphocyte ratio (dNLR) 
in two multinational randomized phase III trials of mCRPC patients receiving first-line 
chemotherapy. In conclusion, the dNLR was prognostic for OS in men with mCRPC 
receiving first-line chemotherapy. We found that an elevated dNLR (≥2) was associated 
with shorter survival irrespective of the received treatment and other known prognostic 
factors. Furthermore, we composed a risk score to predict survival of men with mCRPC 
receiving first-line chemotherapy. Factors included in the final risk score were; age, alkaline 
phosphatase, hemoglobin, duration of initial androgen deprivation therapy, dNLR, and 
the presence of pain at baseline. The composed score and was significantly and inversely 
associated with survival in both databases. The dNLR is a readily available biomarker that 
comes with no extra costs, which can be used for risk stratification in future clinical trials 
and should be incorporated into new prognostic nomograms. In addition, it may provide 
direct prognostic information on patients in daily practice.
In chapter 8 the results of chapters 3-7 are discussed and recommendations for future 
research are provided. In this thesis, we have identified mechanisms of cross-resistance 
between the available therapies in mCRPC. These may ultimately help in defining the 
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optimal drug treatment sequence. Furthermore, we have provided both predictive and 
prognostic factors, which can help to define which patients will benefit the most from 
treatment with docetaxel chemotherapy in mCRPC.
Despite the rapid therapeutic advances, mCRPC is still a lethal disease. Biomarker driven 
studies are key in identifying mechanisms of resistance to new drugs, and developing 
strategies to overcome resistance. Such translational efforts are urgently needed to 
change the current one-size-fits-all approach into a more personalized treatment strategy 
for mCRPC. Novel therapies and drug combinations targeting multiple tumorigenic 
pathways may ultimately turn mCRPC into a chronic rather than a lethal disease.
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De behandeling van het gemetastaseerd castratie-resistent prostaatcarcinoom 
(mCRPC) heeft zich de laatste jaren sterk ontwikkeld met de introductie van verschillende 
nieuwe middelen waaronder cabazitaxel, abiraterone, enzalutamide en radium-223 [1-5]. 
Deze vooruitgang brengt ook nieuwe uitdagingen met zich mee. Het wordt vermoed dat 
er kruisresistentie zou kunnen optreden tussen taxanen (zoals docetaxel en cabazitaxel) 
en androgeen receptor (AR) gerichte middelen abiratrone en enzalutamide. Daarnaast is 
de optimale behandelingsvolgorde voor mCRPC nog onbekend. 
Er is toenemend wetenschappelijk bewijs uit retrospectieve klinische studies, welke 
suggereren dat de effectiviteit van docetaxel verminderd zou zijn in patiënten met mCRPC 
die eerder behandeld zijn met abiraterone [6-8]. Daarnaast zijn er sterke aanwijzingen dat 
de effectiviteit van abiraterone verminderd is na eerdere behandeling met enzalutamide 
en vice versa. [9-12].
Taxanen werken door interactie met microtubili middels polymerisatie, leidend tot 
mitose arrest en apoptose. Recente studies suggereren dat paclitaxel en docetaxel ook 
in staat zijn om AR-translocatie en signalering te inhiberen, hetgeen in mCRPC deels 
verantwoordelijk zou kunnen zijn voor het therapeutisch effect. In hoofdstuk 3 hebben 
we castratie-resistante prostaatkanker (CRPC) cellijnen met verworven resistentie 
voor abiraterone en enzalutamide gebruikt om inzicht te krijgen in mechanismen van 
kruisresistentie tussen docetaxel, cabazitaxel, abiraterone en enzalutamide. In deze 
cellijnen hebben we kruisresistentie waargenomen tussen de taxanen en nieuwe 
hormonale middelen abiraterone en enzalutamide. Als een potentieel mechanisme voor 
kruisresistentie identificeerden we AR translocatie naar de celkern, welke een overlappend 
werkingsmechanisme tussen deze middelen is. De rol van microtubili en het motoreiwit 
dyneine in AR transport is recent aan het licht gekomen in preklinische studies [15,16]. 
In onze studie, hebben we laten zien dat taxanen in staat zijn om AR translocatie naar 
de celkern te remmen als een additioneel werkingsmechanisme. Dit effect zagen we 
ook voor de nieuwe hormonale middelen abiraterone en enzlautamide, hetgeen een 
overlappend werkingsmechanisme identificeert dat potentieel zorgt voor kruisresistentie 
tussen taxanen en deze nieuwe hormonale middelen. 
In hoofdstuk 4 hebben we onze in vitro bevindingen van kruisresistentie tussen 
docetaxel en enzalutamide bevestigd in een muismodel van enzalutamide-resistent 
versus enzalutamide-naïef CRPC. De effectiviteit van docetaxel was verminderd in 
tumoren met verworven resistentie voor enzalutamide (PC346Enza) vergeleken met de 
enzalutamide-naïve tumoren (PC346C). Deze verminderde effectiviteit werd veroorzaakt 
door een verminderde inhibitie van AR translocatie naar de celkern en AR gereguleerde 
genexpressie in enzalutamide-resistente tumoren vergeleken met enzalutamide- naïve 
tumoren. In tegenstelling tot docetaxel, bleef cabazitaxel zeer effectief in enzalutamide-
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resistente tumoren, hetgeen grotere anti-proliferatieve eigenschappen laat zien welke 
onafhankelijk zijn van de AR pathway. Deze bevindingen zijn interessant omdat ze exact 
overeenkomen met klinische studies welke kruisresistentie toonden voor docetaxel, maar 
niet voor cabazitaxel, hetgeen mechanistisch verklaard kan worden door de bevindingen 
in onze xenograft studies [6,7,9,10]. 
In hoofdstuk 5 hebben we de bevindingen uit onze preklinsiche in vivo studies 
klinisch bevestigd in patiënten. Middels data uit een prospectieve, multicenter, 
gerandomiseerde fase 2 studie hebben we de invloed van eerdere therapie abiraterone 
en enzalutamide op de effectiviteit van cabazitaxel onderzocht. In deze studie vonden 
we dat de PSA respons onder behandeling met cabazitaxel vergelijkbaar was tussen 
patiënten met en zonder eerdere hormonale therapie (respectievelijk 34% versus 40%, 
P=0.53). Tevens was de mediane overleving niet significant verschillend tussen mannen 
met en zonder eerdere hormonale therapie, met een overleving van respectievelijk 9.8 
maanden versus 10.6 maanden (logrank P=0.65). Deze bevindingen wijzen er sterk op dat 
er geen kruisresistentie is tussen abiraterone/enzalutamide en cabazitaxel. 
In hoofdstuk 6 hebben we onderzocht welke patiënten het meeste baat hebben 
bij chemotherapie met docetaxel. Hiertoe hebben we een post-hoc analyse uitgevoerd 
op de TAX327 registratie studie. Deze analyse liet zien dat de klinische baat bij docetaxel 
het grootst was voor patiënten met een hoge Gleason score bij diagnose. De mediane 
overleving in mannen met een hoge Gleason score (7-10) was 4.4 maanden (logrank 
P=0.009), vergeleken met 2.9 maanden in de gehele patiëntenpopulatie. Nu de nieuwe 
hormonale middelen abiraterone en enzalutamide ook beschikbaar zijn voor behandeling 
met chemotherapie kan de Gleason score helpen met het selecteren van patiënten die 
de meeste baat hebben bij chemotherapie met docetaxel als eerstelijns therapie voor 
mCRPC.
De neutrofielen-lymfocyten ratio (NLR) is een marker voor systemische inflammatie, 
hetgeen beschreven is als één van de specifieke kenmerken van kanker [17]. In hoofdstuk 
7 hebben we de prognostische en predictieve rol van de afgeleide NLR (dNLR) onderzocht 
in twee multinationale gerandomiseerde fase 3 studies van patiënten met mCRPC die 
eerstelijns chemotherapie ondergingen. Concluderend, was de dNLR geassocieerd met 
overlevingsduur in mannen met mCRPC behandeld met eerstelijns chemotherapie. Een 
verhoogde dNLR (≥2) was geassocieerd met een kortere overlevingsduur, onafhankelijk 
van de ontvangen behandeling en andere prognostische factoren. Vervolgens hebben 
we een risicoscore ontworpen die de overleving van mannen met mCRPC die eerstelijns 
chemotherapie ondergaan kan voorspellen. Factoren die meegewogen zijn in de 
risicoscore zijn; leeftijd, alkalisch fosfatase, hemoglobine, de duur van initiële hormonale 
therapie, dNLR, en de aanwezigheid van pijn. De samengestelde risicoscore was significant 
geassocieerd met overlevingsduur in beide databases. Dit maakt dat de dNLR is een 
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goedkope biomarker is, die klaar is voor klinisch gebruik en de prognose van patiënten 
met mCRPC kan voorspellen.
In hoofdstuk 8 worden hoofdstukken 3-7 in perspectief geplaatst en worden 
aanbevelingen voor toekomstig onderzoek gedaan. In dit proefschrift hebben we 
mechanismen van kruisresistentie tussen de beschikbare therapieën voor mCRPC 
geïdentificeerd. Deze bevindingen kunnen uiteindelijk bijdragen aan het vinden van 
de optimale behandelingsvolgorde voor patiënten met mCRPC. Hiernaast hebben we 
zowel predictieve als prognostische factoren gevonden welke kunnen helpen met het 
identificeren van patiënten die de meeste baat hebben bij chemotherapie met docetaxel. 
Ondanks de snelle vooruitgang in de behandeling is mCRPC nog steeds een 
dodelijke ziekte. Biomarker gedreven studies zijn de sleutel in het identificeren van 
resistentiemechanismen voor nieuwe middelen, en in het ontwikkelen van strategieën om 
resistentie te voorkomen. Zulke translationele studies zijn dringend nodig om de huidige 
one-size-fits-all aanpak te veranderen in een gepersonaliseerde behandeling voor mCRPC. 
Nieuwe therapieën en behandelcombinaties gericht op meerdere tumorpathways zouden 
van mCRPC uiteindelijk een chronische in plaats van een dodelijke ziekte kunnen maken.
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Dr. van Weerden, beste Wytske, dankzij jouw uitgebreide kennis en kunde over 
prostaatkankermodellen hebben we vele mooie experimenten kunnen opzetten. Ik wil 
je bedanken voor onze mooie samenwerking en talloze uren aan wetenschappelijke 
discussies. Je hebt me wegwijs gemaakt in het preklinisch onderzoek, hetgeen me zeer 
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inspirerend. Als ik op zondag in het lab ging werken kon ik in ieder geval rekenen op de 
aanwezigheid van één persoon, en dat was prof. Jenster zelf. Waar beter kan je immers je 
vrije zondagmiddag besteden?!  Door jouw bijscholing begrijp ik nu enigszins het reilen 
en zeilen van cellen, DNA, en RNA. Bedankt voor je geduld!
De leescommissie, Prof. Zwarthoff, beste Ellen, Prof. van den Bent, en Prof. Gelderblom; 
hartelijk dank voor het zorgvuldig lezen en beoordelen van mijn proefschrift.
Prof. Bangma, beste Chris, je hebt mij geïntroduceerd in de wondere wereld van de 
urologie, en wetenschappelijk onderzoek. Onder jouw leiding en scherpzinnige visie 
begon ik met mijn afstudeeronderzoek naar prostaat MRI. Dankzij deze kansen en je 
immer enthousiasmerende kijk op wetenschap ben ik uiteindelijk dit promotieonderzoek 
gaan doen.
Prof. Mathijssen, beste Ron, en Erik Wiemer, bedankt voor jullie zeer waardevolle input en 
resultaat gerichte aanpak tijdens onze maandelijkse besprekingen. Deze heb ik altijd als 
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erg nuttig ervaren en waren essentieel voor de voortgang van het onderzoek. Hopelijk 
kunnen we onze samenwerking continueren als ik over 1,5 jaar terugkeer naar het 
Erasmus MC.
Dr. van Royen, beste Martin, ondanks dat we een totaal verschillende achtergrond 
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Robert van Soest werd geboren op 3 juni 1987 te Rotterdam. Hij groeide op in Rotterdam 
en behaalde hier zijn gymnasium diploma in 2005. In hetzelfde jaar begon hij met de 
studie geneeskunde aan de Erasmus Universiteit Rotterdam, alwaar hij in 2012 zijn 
artsenbul kreeg uitgereikt. Tijdens de co-schappen werd zijn interesse in de urologie al 
snel gewekt met als gevolg een oudste co-schap en afstudeeronderzoek op de afdeling 
urologie van het Erasmus MC onder leiding van Prof. C.H. Bangma. Aansluitend ging hij 
verder met een promotietraject op de afdelingen urologie en interne-oncologie van het 
Erasmus MC onder supervisie van Prof. R. de Wit, Prof. G. Jenster en Dr. W. van Weerden. 
Na een korte stage als arts-assistent urologie in het St. Franciscus Gasthuis te Rotterdam 
werd hij in 2014 aangenomen voor de opleiding tot uroloog. Sinds januari 2015 is hij 
begonnen met de vooropleiding heelkunde in het St. Franciscus Gasthuis. In 2017 zal hij 
zijn opleiding urologie voortzetten in het Erasmus MC te Rotterdam.
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workload 
(eCTs)
general courses
English biomedical writing and communication 2012-2013 4
Course on molecular diagnostics 2012 1
Course on microscopic image analysis 2012 0.5
Course on survival analysis 2013 0.5
Biostatistical methods and principles 2013 2
Clinical research course on Good Clinical Practice (BROK) 2013 1.5
seminars and workshops
Department of Urology Journal club 2012-2014 1
Department of Urology PhD meeting 2012-2014 0.5
Department of Urology ‘refereeravond’ 2012-2014 1
presentations national
NVU voorjaarsvergadering/najaarsvergadering (Vlietstraprijs) 2012-2014 1
Dutch uro-oncologic study group (DUOS) 2012-2014 1.5
IKNL netwerkdagen 2013 0.5
Tour d’Europe Rotterdam 2014 0.5
presentations international
ASCO Annual meeting (merit award) 2013-2014 1.5
EAU Annual Congress (poster award) 2013-2014 0.5
ASCO-GU meeting (merit award) 2013 0.5
European Cancer Conference 2013 0.5
Prostate Cancer Translational Research in Europe 2013 1
ESMO congress 2014 0.5
Interactive Genitourinary Cancer Conference (faculty member) 2014 1.5
EAU Annual Congress (faculty member) 2015 1
lecturing
‘The androgen receptor’ Medical students Erasmus MC 2012-2014 1.5
‘Urological anatomy’ Medical students Erasmus MC 2012-2013 1
Supervision of master thesis, students biopharmaceutical sciences, LUMC  2013-2014 4
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